Loading...

Furst Daniel

TitleProfessor
InstitutionUniversity of California Los Angeles
DepartmentMedicine
AddressUCLA Med-Rheum
BOX 951670
32-59 Rehab
Los Angeles CA 90095
Phone310-206-4267
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Provisional Combined Response Index For Patients With Diffuse Systemic Sclerosis
    NIH/NIAMS U01AR055057Aug 1, 2007 - Jul 31, 2012
    Role: Principal Investigator
    ORAL CYCLOPHOSPHAMIDE VS ORAL PLACEBO IN SSC ALVEOLITIS
    NIH/NHLBI U01HL060823Aug 10, 1999 - Jun 30, 2004
    Role: Principal Investigator
    ANALYSIS OF CONTROLLED TRIAL OF CHLORAMBUCIL VS. PLACEBO
    FDA R01FD001273Nov 15, 1983 - Mar 31, 1986
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Li H, Furst DE, Jin H, Sun C, Wang X, Yang L, He J, Wang Y, Liu A. High-frequency ultrasound of the skin in systemic sclerosis: an exploratory study to examine correlation with disease activity and to define the minimally detectable difference. Arthritis Res Ther. 2018 Aug 16; 20(1):181. PMID: 30115105.
      View in: PubMed
    2. Bartoli F, Bae S, Cometi L, Matucci Cerinic M, Furst DE. Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018. Expert Rev Clin Immunol. 2018 Jun 21. PMID: 29925278.
      View in: PubMed
    3. Dougherty DH, Kwakkenbos L, Carrier ME, Salazar G, Assassi S, Baron M, Bartlett SJ, Furst DE, Gottesman K, van den Hoogen F, Malcarne VL, Mouthon L, Nielson WR, Poiraudeau S, Sauvé M, Boire G, Bruns A, Chung L, Denton C, Dunne JV, Fortin P, Frech T, Gill A, Gordon J, Herrick AL, Hinchcliff M, Hudson M, Johnson SR, Jones N, Kafaja S, Larché M, Manning J, Pope J, Spiera R, Steen V, Sutton E, Thorne C, Wilcox P, Thombs BD, Mayes MD. The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. Rheumatology (Oxford). 2018 Jun 02. PMID: 29868924.
      View in: PubMed
    4. Kafaja S, Valera I, Divekar AA, Saggar R, Abtin F, Furst DE, Khanna D, Singh RR. pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis. JCI Insight. 2018 May 03; 3(9). PMID: 29720568.
      View in: PubMed
    5. Pappas DA, Nyberg F, Kremer JM, Lampl K, Reed GW, Horne L, Ho M, Onofrei A, Malaviya AN, Rillo OL, Radominski SC, Gal J, Gibofsky A, Popkova TV, Laurindo L, Kerzberg EM, Zahora R, Pons-Estel BA, Curtis JR, Furst DE, Greenberg JD. Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study. Clin Rheumatol. 2018 Apr 25. PMID: 29696436.
      View in: PubMed
    6. Ingegnoli F, Schioppo T, Allanore Y, Caporali R, Colaci M, Distler O, Furst DE, Hunzelmann N, Iannone F, Khanna D, Matucci-Cerinic M. Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus. Semin Arthritis Rheum. 2018 Apr 04. PMID: 29706243.
      View in: PubMed
    7. Sullivan KM, Goldmuntz EA, Furst DE. Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med. 2018 03 15; 378(11):1066-1067. PMID: 29539292.
      View in: PubMed
    8. Suliman YA, Kafaja S, Fitzgerald J, Wortsman X, Grotts J, Matucci-Cerrinic M, Ranganath VK, Furst DE. Ultrasound characterization of cutaneous ulcers in systemic sclerosis. Clin Rheumatol. 2018 Jun; 37(6):1555-1561. PMID: 29525847.
      View in: PubMed
    9. Merz EL, Kwakkenbos L, Carrier ME, Gholizadeh S, Mills SD, Fox RS, Jewett LR, Williamson H, Harcourt D, Assassi S, Furst DE, Gottesman K, Mayes MD, Moss TP, Thombs BD, Malcarne VL. Factor structure and convergent validity of the Derriford Appearance Scale-24 using standard scoring versus treating 'not applicable' responses as missing data: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. BMJ Open. 2018 03 06; 8(3):e018641. PMID: 29511009.
      View in: PubMed
    10. Rubbert-Roth A, Furst DE, Nebesky JM, Jin A, Berber E. A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases. Rheumatol Ther. 2018 Jun; 5(1):21-42. PMID: 29502236.
      View in: PubMed
    11. Namas R, Tashkin DP, Furst DE, Wilhalme H, Tseng CH, Roth MD, Kafaja S, Volkmann E, Clements PJ, Khanna D. Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials. Arthritis Care Res (Hoboken). 2018 Mar; 70(3):439-444. PMID: 28544580.
      View in: PubMed
    12. Fox RS, Kwakkenbos L, Carrier ME, Mills SD, Gholizadeh S, Jewett LR, Roesch SC, Merz EL, Assassi S, Furst DE, Gottesman K, Mayes MD, Thombs BD, Malcarne VL. Validation of the Brief Fear of Negative Evaluation Scale-II in patients with systemic sclerosis: A Scleroderma Patient-centered Intervention Network Cohort study. Arthritis Care Res (Hoboken). 2018 Feb 06. PMID: 29409146.
      View in: PubMed
    13. Johnson SR, Khanna D, Allanore Y, Matucci-Cerinic M, Furst DE. Systemic Sclerosis Trial Design Moving Forward. J Scleroderma Relat Disord. 2016 May-Aug; 1(2):177-180. PMID: 29492470.
      View in: PubMed
    14. Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein JS, Wallace D, Craciunescu O, Khanna D, Folz RJ, Goldin J, St Clair EW, Seibold JR, Phillips K, Mineishi S, Simms RW, Ballen K, Wener MH, Georges GE, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClercq S, Brasington R, Csuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med. 2018 01 04; 378(1):35-47. PMID: 29298160.
      View in: PubMed
    15. Gorlova OY, Li Y, Gorlov I, Ying J, Chen WV, Assassi S, Reveille JD, Arnett FC, Zhou X, Bossini-Castillo L, Lopez-Isac E, Acosta-Herrera M, Gregersen PK, Lee AT, Steen VD, Fessler BJ, Khanna D, Schiopu E, Silver RM, Molitor JA, Furst DE, Kafaja S, Simms RW, Lafyatis RA, Carreira P, Simeon CP, Castellvi I, Beltran E, Ortego N, Amos CI, Martin J, Mayes MD. Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations. PLoS One. 2018; 13(1):e0189498. PMID: 29293537.
      View in: PubMed
    16. Woodworth TG, Suliman YA, Li W, Furst DE, Clements P. Scleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol. 2018 Feb; 14(2):137. PMID: 29292373.
      View in: PubMed
    17. Arnold MB, Khanna D, Denton CP, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE, Pope JE. Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. Rheumatology (Oxford). 2018 01 01; 57(1):152-157. PMID: 29077900.
      View in: PubMed
    18. Barroso NS, Miller EZ, Furst DE. A Case Series on Patients on Tofacitinib in Combination With a Biologic. J Clin Rheumatol. 2017 Dec 27. PMID: 29280829.
      View in: PubMed
    19. Kafaja S, Clements PJ, Wilhalme H, Tseng CH, Furst DE, Kim GH, Goldin J, Volkmann ER, Roth MD, Tashkin DP, Khanna D. Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II). Am J Respir Crit Care Med. 2017 Nov 03. PMID: 29099620.
      View in: PubMed
    20. Hsu VM, Denton CP, Domsic RT, Furst DE, Rischmueller M, Stanislav M, Steen VD, Distler JHW, Korish S, Cooper A, Choi S, Schafer PH, Horan G, Hough DR. Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study. J Rheumatol. 2018 Mar; 45(3):405-410. PMID: 29093152.
      View in: PubMed
    21. Rigby WFC, Lampl K, Low JM, Furst DE. Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs. Int J Rheumatol. 2017; 2017:9614241. PMID: 29225625.
      View in: PubMed
    22. Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis. 2018 Feb; 77(2):212-220. PMID: 29066464.
      View in: PubMed
    23. Wang Y, Gargani L, Barskova T, Furst DE, Cerinic MM. Usefulness of lung ultrasound B-lines in connective tissue disease-associated interstitial lung disease: a literature review. Arthritis Res Ther. 2017 Sep 18; 19(1):206. PMID: 28923086.
      View in: PubMed
    24. Weinblatt ME, Bingham CO, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, VanLunen B, Ecoffet C, Cioffi C, Emery P. A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. Arthritis Rheumatol. 2017 10; 69(10):1937-1948. PMID: 28666080.
      View in: PubMed
    25. Khanna D, Hays RD, Furst DE. Functional disability and other health-related quality-of-life domains: points to consider for clinical trials in systemic sclerosis. Rheumatology (Oxford). 2017 09 01; 56(suppl_5):v17-v22. PMID: 28992164.
      View in: PubMed
    26. Galluccio F, Allanore Y, Czirjak L, Furst DE, Khanna D, Matucci-Cerinic M. Points to consider for skin ulcers in systemic sclerosis. Rheumatology (Oxford). 2017 09 01; 56(suppl_5):v67-v71. PMID: 28992171.
      View in: PubMed
    27. Kumánovics G, Péntek M, Bae S, Opris D, Khanna D, Furst DE, Czirják L. Assessment of skin involvement in systemic sclerosis. Rheumatology (Oxford). 2017 09 01; 56(suppl_5):v53-v66. PMID: 28992173.
      View in: PubMed
    28. Clements P, Allanore Y, Furst DE, Khanna D. Points to consider for designing trials in systemic sclerosis patients with arthritic involvement. Rheumatology (Oxford). 2017 09 01; 56(suppl_5):v23-v26. PMID: 28992165.
      View in: PubMed
    29. Cutolo M, Smith V, Furst DE, Khanna D, Herrick AL. Points to consider-Raynaud's phenomenon in systemic sclerosis. Rheumatology (Oxford). 2017 09 01; 56(suppl_5):v45-v48. PMID: 28992170.
      View in: PubMed
    30. Galluccio F, Müller-Ladner U, Furst DE, Khanna D, Matucci-Cerinic M. Points to consider in renal involvement in systemic sclerosis. Rheumatology (Oxford). 2017 09 01; 56(suppl_5):v49-v52. PMID: 28992172.
      View in: PubMed
    31. Furst DE, Braun-Moscovic Y, Khanna D. Points to consider for clinical trials of the gastrointestinal tract in systemic sclerosis. Rheumatology (Oxford). 2017 09 01; 56(suppl_5):v4-v11. PMID: 28992166.
      View in: PubMed
    32. Walker UA, Clements PJ, Allanore Y, Distler O, Oddis CV, Khanna D, Furst DE. Muscle involvement in systemic sclerosis: points to consider in clinical trials. Rheumatology (Oxford). 2017 09 01; 56(suppl_5):v38-v44. PMID: 28992167.
      View in: PubMed
    33. Humbert M, Singh M, Furst DE, Khanna D, Seibold JR. Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials. Rheumatology (Oxford). 2017 09 01; 56(suppl_5):v33-v37. PMID: 28992168.
      View in: PubMed
    34. Allanore Y, Distler O, Walker UA, Khanna D, Furst DE, Meune C. Points to consider when doing a trial primarily involving the heart. Rheumatology (Oxford). 2017 09 01; 56(suppl_5):v12-v16. PMID: 28992169.
      View in: PubMed
    35. Khanna D, Seibold J, Goldin J, Tashkin DP, Furst DE, Wells A. Interstitial lung disease points to consider for clinical trials in systemic sclerosis. Rheumatology (Oxford). 2017 09 01; 56(suppl_5):v27-v32. PMID: 28992174.
      View in: PubMed
    36. Bartlett SJ, Barbic SP, Bykerk VP, Choy EH, Alten R, Christensen R, den Broeder A, Fautrel B, Furst DE, Guillemin F, Hewlett S, Leong AL, Lyddiatt A, March L, Montie P, Pohl C, Scholte Voshaar M, Woodworth TG, Bingham CO. Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report. J Rheumatol. 2017 Oct; 44(10):1536-1543. PMID: 28811351.
      View in: PubMed
    37. Winthrop KL, Strand V, van der Heijde D, Mease P, Crow M, Weinblatt M, Bathon J, Burmester GR, Dougados M, Kay J, Mariette X, Van Vollenhoven R, Sieper J, Melchers F, Breedfeld FC, Kalden J, Smolen JS, Furst DE. The unmet need in rheumatology: Reports from the targeted therapies meeting 2017. Clin Immunol. 2018 Jan; 186:87-93. PMID: 28811201.
      View in: PubMed
    38. Aly AM, Furst DE. Update of sarilumb to treat rheumatoid arthritis based on randomized clinical trials: a systematic review. Expert Rev Clin Immunol. 2017 08; 13(8):741-752. PMID: 28689441.
      View in: PubMed
    39. Kwakkenbos L, Thombs BD, Khanna D, Carrier ME, Baron M, Furst DE, Gottesman K, van den Hoogen F, Malcarne VL, Mayes MD, Mouthon L, Nielson WR, Poiraudeau S, Riggs R, Sauvé M, Wigley F, Hudson M, Bartlett SJ. Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. Rheumatology (Oxford). 2017 08 01; 56(8):1302-1311. PMID: 28431140.
      View in: PubMed
    40. Woodworth TG, Morgacheva O, Pimienta OL, Troum OM, Ranganath VK, Furst DE. Examining the validity of the rheumatoid arthritis magnetic resonance imaging score according to the OMERACT filter-a systematic literature review. Rheumatology (Oxford). 2017 07 01; 56(7):1177-1188. PMID: 28398508.
      View in: PubMed
    41. Gordon KB, Leonardi CL, Furst DE, Bhatia N, Eichenfield LF, Beleznay K. Highlights of Skin Disease Education Foundation's 41st Annual Hawaii Dermatology Seminar™. Semin Cutan Med Surg. 2017 06; 36(4S):S52-S59. PMID: 28745729.
      View in: PubMed
    42. Volkmann ER, Tashkin DP, Li N, Roth MD, Khanna D, Hoffmann-Vold AM, Kim G, Goldin J, Clements PJ, Furst DE, Elashoff RM. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. Arthritis Rheumatol. 2017 07; 69(7):1451-1460. PMID: 28376288.
      View in: PubMed
    43. Abozaid HSM, Imam HMK, Abdelaziz MM, El-Hammady DH, Fathi NA, Furst DE. High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in Systemic Sclerosis. Semin Arthritis Rheum. 2017 Dec; 47(3):403-408. PMID: 28624173.
      View in: PubMed
    44. Finger ME, Boonen A, Woodworth TG, Escorpizo R, Christensen R, Nielsen SM, Leong AL, Scholte Voshaar M, Flurey CA, Milman N, Verstappen SM, Alten R, Guillemin F, Kloppenburg M, Beaton DE, Tugwell PS, March LM, Furst DE, Pohl C. An OMERACT Initiative Toward Consensus to Identify and Characterize Candidate Contextual Factors: Report from the Contextual Factors Working Group. J Rheumatol. 2017 Nov; 44(11):1734-1739. PMID: 28461648.
      View in: PubMed
    45. Gholizadeh S, Mills SD, Fox RS, Merz EL, Roesch SC, Clements PJ, Kafaja S, Furst DE, Khanna D, Malcarne VL. Structural Validity of the Rheumatology Attitudes Index in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life Study. J Rheumatol. 2017 Jun; 44(6):795-798. PMID: 28412704.
      View in: PubMed
    46. Gentil CA, Gammill HS, Luu CT, Mayes MD, Furst DE, Nelson JL. Characterization of the HLA-DRß1 third hypervariable region amino acid sequence according to charge and parental inheritance in systemic sclerosis. Arthritis Res Ther. 2017 Mar 07; 19(1):46. PMID: 28270189.
      View in: PubMed
    47. Furst DE, Tran M, Sullivan E, Pike J, Piercy J, Herrera V, Palmer JB. Misalignment between physicians and patient satisfaction with psoriatic arthritis disease control. Clin Rheumatol. 2017 Sep; 36(9):2045-2054. PMID: 28238086.
      View in: PubMed
    48. Tesser JR, Furst DE, Jacobs I. Biosimilars and the extrapolation of indications for inflammatory conditions. Biologics. 2017; 11:5-11. PMID: 28255229.
      View in: PubMed
    49. Senftleber NK, Nielsen SM, Andersen JR, Bliddal H, Tarp S, Lauritzen L, Furst DE, Suarez-Almazor ME, Lyddiatt A, Christensen R. Marine Oil Supplements for Arthritis Pain: A Systematic Review and Meta-Analysis of Randomized Trials. Nutrients. 2017 Jan 06; 9(1). PMID: 28067815.
      View in: PubMed
    50. Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, Distler O, Foeldvari I, Kuwana M, Matucci-Cerinic M, Mayes M, Medsger T, Merkel PA, Pope JE, Seibold JR, Steen V, Stevens W, Denton CP. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord. 2017 Jan-Apr; 2(1):11-18. PMID: 28516167.
      View in: PubMed
    51. Volkmann ER, Tashkin DP, Roth MD, Clements PJ, Khanna D, Furst DE, Mayes M, Charles J, Tseng CH, Elashoff RM, Assassi S. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. Arthritis Res Ther. 2016 Dec 30; 18(1):305. PMID: 28038680.
      View in: PubMed
    52. Tashkin DP, Volkmann ER, Tseng CH, Roth MD, Khanna D, Furst DE, Clements PJ, Theodore A, Kafaja S, Kim GH, Goldin J, Ariolla E, Elashoff RM. Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II. Chest. 2017 Apr; 151(4):813-820. PMID: 28012804.
      View in: PubMed
    53. Bruni C, Praino E, Guiducci S, Bellando-Randone S, Furst DE, Matucci-Cerinic M. Hydroxychloroquine and joint involvement in systemic sclerosis: Preliminary beneficial results from a retrospective case-control series of an EUSTAR center. Joint Bone Spine. 2017 Dec; 84(6):747-748. PMID: 27932280.
      View in: PubMed
    54. Chung L, Fairchild RM, Furst DE, Li S, Alkassab F, Bolster MB, Csuka ME, Derk CT, Domsic RT, Fischer A, Frech TM, Gomberg-Maitland M, Gordon JK, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TAJ, Molitor JA, Preston IR, Schiopu E, Shapiro L, Hant F, Silver R, Simms R, Varga J, Steen VD, Zamanian RT. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 106(4):106-113. PMID: 27908301.
      View in: PubMed
    55. Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, Distler O, Clements P, Cutolo M, Czirjak L, Damjanov N, Del Galdo F, Denton CP, Distler JHW, Foeldvari I, Figelstone K, Frerix M, Furst DE, Guiducci S, Hunzelmann N, Khanna D, Matucci-Cerinic M, Herrick AL, van den Hoogen F, van Laar JM, Riemekasten G, Silver R, Smith V, Sulli A, Tarner I, Tyndall A, Welling J, Wigley F, Valentini G, Walker UA, Zulian F, Müller-Ladner U. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017 Aug; 76(8):1327-1339. PMID: 27941129.
      View in: PubMed
    56. Klokker L, Tugwell P, Furst DE, Devoe D, Williamson P, Terwee CB, Suarez-Almazor ME, Strand V, Woodworth T, Leong AL, Goel N, Boers M, Brooks PM, Simon LS, Christensen R. Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group. J Rheumatol. 2017 Dec; 44(12):1916-1919. PMID: 27744393.
      View in: PubMed
    57. Sullivan KM, Shah A, Sarantopoulos S, Furst DE. Review: Hematopoietic Stem Cell Transplantation for Scleroderma: Effective Immunomodulatory Therapy for Patients With Pulmonary Involvement. Arthritis Rheumatol. 2016 Oct; 68(10):2361-71. PMID: 27213276.
      View in: PubMed
    58. Hay MC, Furst DE. The Responsibilites of Daily Life May Interfere With Adherence to Medications in Patients With Rheumatoid Arthritis (RA) and Systemic Sclerosis (SSc). J Clin Rheumatol. 2016 Oct; 22(7):392. PMID: 27660944.
      View in: PubMed
    59. Woodworth TG, Suliman YA, Li W, Furst DE, Clements P. Scleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol. 2016 11; 12(11):678-691. PMID: 27641135.
      View in: PubMed
    60. Tarp S, Furst DE, Dossing A, Østergaard M, Lorenzen T, Hansen MS, Singh JA, Choy EH, Boers M, Suarez-Almazor ME, Kristensen LE, Bliddal H, Christensen R. Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials. Semin Arthritis Rheum. 2017 06; 46(6):699-708. PMID: 27769592.
      View in: PubMed
    61. Winthrop KL, Strand V, van der Heijde DM, Mease PJ, Crow MK, Weinblatt M, Bathon JM, Buch MH, Burmester GR, Dougados M, Kay J, Mariette X, Breedveld FC, Kalden JR, Smolen JS, Furst DE. The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016. Clin Exp Rheumatol. 2016 Jul-Aug; 34(4 Suppl 98):69-76. PMID: 27586809.
      View in: PubMed
    62. Jewett LR, Kwakkenbos L, Carrier ME, Malcarne VL, Bartlett SJ, Furst DE, Gottesman K, Mayes MD, Assassi S, Harcourt D, Williamson H, Johnson SR, Körner A, Steen V, Fox RS, Gholizadeh S, Mills SD, Molnar JC, Rice DB, Thombs BD. Examination of the association of sex and race/ethnicity with appearance concerns: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. Clin Exp Rheumatol. 2016 Sep-Oct; 34 Suppl 100(5):92-99. PMID: 27494308.
      View in: PubMed
    63. Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 09; 4(9):708-719. PMID: 27469583.
      View in: PubMed
    64. Bartoli F, Bruni C, Cometi L, Blagojevic J, Fiori G, Tofani L, Galluccio F, Furst DE, Matucci Cerinic M. Premedication prevents infusion reactions and improves retention rate during infliximab treatment. Clin Rheumatol. 2016 Nov; 35(11):2841-2845. PMID: 27436188.
      View in: PubMed
    65. Amarilyo G, Tarp S, Foeldvari I, Cohen N, Pope TD, Woo JM, Christensen R, Furst DE. Biological agents in polyarticular juvenile idiopathic arthritis: A meta-analysis of randomized withdrawal trials. Semin Arthritis Rheum. 2016 12; 46(3):312-318. PMID: 27989499.
      View in: PubMed
    66. Fleischmann R, Weinblatt ME, Schiff M, Khanna D, Maldonado MA, Nadkarni A, Furst DE. Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016 Jul; 68(7):907-13. PMID: 26473625.
      View in: PubMed
    67. Zhang Y, Lee SY, Zhang Y, Furst D, Fitzgerald J, Ozcan A. Wide-field imaging of birefringent synovial fluid crystals using lens-free polarized microscopy for gout diagnosis. Sci Rep. 2016 06 30; 6:28793. PMID: 27356625.
      View in: PubMed
    68. Volkmann ER, Chang YL, Barroso N, Furst DE, Clements PJ, Gorn AH, Roth BE, Conklin JL, Getzug T, Borneman J, McGovern DP, Tong M, Jacobs JP, Braun J. Association of Systemic Sclerosis With a Unique Colonic Microbial Consortium. Arthritis Rheumatol. 2016 06; 68(6):1483-92. PMID: 26749064.
      View in: PubMed
    69. Miele CH, Schwab K, Saggar R, Duffy E, Elashoff D, Tseng CH, Weigt S, Charan D, Abtin F, Johannes J, Derhovanessian A, Conklin J, Ghassemi K, Khanna D, Siddiqui O, Ardehali A, Hunter C, Kwon M, Biniwale R, Lo M, Volkmann E, Torres Barba D, Belperio JA, Sayah D, Mahrer T, Furst DE, Kafaja S, Clements P, Shino M, Gregson A, Kubak B, Lynch JP, Ross D, Saggar R. Lung Transplant Outcomes in Systemic Sclerosis with Significant Esophageal Dysfunction. A Comprehensive Single-Center Experience. Ann Am Thorac Soc. 2016 Jun; 13(6):793-802. PMID: 27078625.
      View in: PubMed
    70. Bartoli F, Fiori G, Braschi F, Amanzi L, Bruni C, Blagojevic J, Bellando-Randone S, Cometi L, de Souza Mueller C, Guiducci S, Rasero L, Epifani F, Furst DE, Matucci-Cerinic M. Calcinosis in systemic sclerosis: subsets, distribution and complications. Rheumatology (Oxford). 2016 09; 55(9):1610-4. PMID: 27241706.
      View in: PubMed
    71. Bykerk VP, Bingham CO, Choy EH, Lin D, Alten R, Christensen R, Furst DE, Hewlett S, Leong A, March L, Woodworth T, Boire G, Haraoui B, Hitchon C, Jamal S, Keystone EC, Pope J, Tin D, Thorne JC, Bartlett SJ. Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set. RMD Open. 2016; 2(1):e000225. PMID: 27252895; PMCID: PMC4885442.
    72. Khanna D, Denton CP, Merkel PA, Krieg T, Le Brun FO, Marr A, Papadakis K, Pope J, Matucci-Cerinic M, Furst DE. Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials. JAMA. 2016 May 10; 315(18):1975-88. PMID: 27163986.
      View in: PubMed
    73. Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Müller-Ladner U, Lafyatis R, Stifano G, Spotswood H, Chen-Harris H, Dziadek S, Morimoto A, Sornasse T, Siegel J, Furst DE. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016 Jun 25; 387(10038):2630-2640. PMID: 27156934.
      View in: PubMed
    74. Doaty S, Agrawal H, Bauer E, Furst DE. Infection and Lupus: Which Causes Which? Curr Rheumatol Rep. 2016 Mar; 18(3):13. PMID: 26951251.
      View in: PubMed
    75. Lammi MR, Mathai SC, Saketkoo LA, Domsic RT, Bojanowski C, Furst DE, Steen VD. Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension. Arthritis Rheumatol. 2016 Mar; 68(3):740-8. PMID: 26479414; PMCID: PMC4996356 [Available on 03/01/17].
    76. Combe B, Furst DE, Keystone EC, van der Heijde D, Luijtens K, Ionescu L, Goel N, Emery P. Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials. Arthritis Care Res (Hoboken). 2016 Mar; 68(3):299-307. PMID: 26238672.
      View in: PubMed
    77. Scheiman-Elazary A, Duan L, Shourt C, Agrawal H, Ellashof D, Cameron-Hay M, Furst DE. The Rate of Adherence to Antiarthritis Medications and Associated Factors among Patients with Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis. J Rheumatol. 2016 Mar; 43(3):512-23. PMID: 26879354.
      View in: PubMed
    78. Peterfy C, Burmester GR, Bykerk VP, Combe BG, DiCarlo JC, Furst DE, Huizinga TW, Wong DA, Conaghan PG, Emery P. Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis. Ann Rheum Dis. 2016 Aug; 75(8):1501-5. PMID: 26865601; PMCID: PMC4975847.
    79. Khanna D, Berrocal VJ, Giannini EH, Seibold JR, Merkel PA, Mayes MD, Baron M, Clements PJ, Steen V, Assassi S, Schiopu E, Phillips K, Simms RW, Allanore Y, Denton CP, Distler O, Johnson SR, Matucci-Cerinic M, Pope JE, Proudman SM, Siegel J, Wong WK, Wells AU, Furst DE. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. 2016 Feb; 68(2):299-311. PMID: 26808827; PMCID: PMC4826472 [Available on 02/01/17].
    80. Khanna D, Berrocal VJ, Giannini EH, Seibold JR, Merkel PA, Mayes MD, Baron M, Clements PJ, Steen V, Assassi S, Schiopu E, Phillips K, Simms RW, Allanore Y, Denton CP, Distler O, Johnson SR, Matucci-Cerinic M, Pope JE, Proudman SM, Siegel J, Wong WK, Wells AU, Furst DE. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis Care Res (Hoboken). 2016 Feb; 68(2):167-78. PMID: 26806474; PMCID: PMC4818571 [Available on 02/01/17].
    81. Amarilyo G, Furst DE, Woo JM, Li W, Bliddal H, Christensen R, Tarp S. Agreements and Discrepancies between FDA Reports and Journal Papers on Biologic Agents Approved for Rheumatoid Arthritis: A Meta-Research Project. PLoS One. 2016; 11(1):e0147556. PMID: 26808309; PMCID: PMC4725722.
    82. Wu M, Assassi S, Salazar GA, Pedroza C, Gorlova OY, Chen WV, Charles J, Taing ML, Liao K, Wigley FM, Hummers LK, Shah AA, Hinchcliff M, Khanna D, Schiopu E, Phillips K, Furst DE, Steen V, Baron M, Hudson M, Zhou X, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, Simms RW, Silver RM, Frech TM, Fessler BJ, Fritzler MJ, Molitor JA, Segal BM, Movahedian M, Martín J, Varga J, Mayes MD. Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. Arthritis Res Ther. 2016 Jan 20; 18:20. PMID: 26792595; PMCID: PMC4719560.
    83. Khanna D, Nagaraja V, Tseng CH, Abtin F, Suh R, Kim G, Wells A, Furst DE, Clements PJ, Roth MD, Tashkin DP, Goldin J. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. Arthritis Res Ther. 2015 Dec 23; 17:372. PMID: 26704522; PMCID: PMC4718035.
    84. Tarp S, Amarilyo G, Foeldvari I, Christensen R, Woo JM, Cohen N, Pope TD, Furst DE. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Rheumatology (Oxford). 2016 Apr; 55(4):669-79. PMID: 26628580.
      View in: PubMed
    85. Dossing A, Tarp S, Furst DE, Gluud C, Wells GA, Beyene J, Hansen BB, Bliddal H, Christensen R. Modified intention-to-treat analysis did not bias trial results. J Clin Epidemiol. 2016 Apr; 72:66-74. PMID: 26562052.
      View in: PubMed
    86. Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016 Jan; 68(1):1-25. PMID: 26545825.
      View in: PubMed
    87. Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016 Jan; 68(1):1-26. PMID: 26545940.
      View in: PubMed
    88. Assassi S, Swindell WR, Wu M, Tan FD, Khanna D, Furst DE, Tashkin DP, Jahan-Tigh RR, Mayes MD, Gudjonsson JE, Chang JT. Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis. Arthritis Rheumatol. 2015 Nov; 67(11):3016-26. PMID: 26238292.
      View in: PubMed
    89. Christensen AW, Tarp S, Furst DE, Døssing A, Amris K, Bliddal H, Taylor PC, Christensen R. Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological Study. PLoS One. 2015; 10(9):e0136982. PMID: 26360583; PMCID: PMC4567072.
    90. Braun-Moscovici Y, Braun M, Khanna D, Balbir-Gurman A, Furst DE. What tests should you use to assess small intestinal bacterial overgrowth in systemic sclerosis? Clin Exp Rheumatol. 2015 Jul-Aug; 33(4 Suppl 91):S117-22. PMID: 26339892.
      View in: PubMed
    91. van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB. Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years. J Rheumatol. 2015 Oct; 42(10):1761-6. PMID: 26276965.
      View in: PubMed
    92. Thomas SS, Borazan N, Barroso N, Duan L, Taroumian S, Kretzmann B, Bardales R, Elashoff D, Vangala S, Furst DE. Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis. BioDrugs. 2015 Aug; 29(4):241-58. PMID: 26280210.
      View in: PubMed
    93. Furst DE, Kavanaugh A, Florentinus S, Kupper H, Karunaratne M, Birbara CA. Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy. Rheumatology (Oxford). 2015 Dec; 54(12):2188-97. PMID: 26199453.
      View in: PubMed
    94. Meune C, Khanna D, Aboulhosn J, Avouac J, Kahan A, Furst DE, Allanore Y. A right ventricular diastolic impairment is common in systemic sclerosis and is associated with other target-organ damage. Semin Arthritis Rheum. 2016 Feb; 45(4):439-45. PMID: 26272194.
      View in: PubMed
    95. Volkmann ER, Tashkin DP, Li N, Furst DE, Clements PJ, Elashoff RM. Development of a Composite Outcome Measure for Systemic Sclerosis Related Interstitial Lung Disease. Rheumatology (Sunnyvale). 2015 Jun; 5(2). PMID: 28856069.
      View in: PubMed
    96. Mills SD, Fox RS, Merz EL, Clements PJ, Kafaja S, Malcarne VL, Furst DE, Khanna D. Evaluation of the Satisfaction with Appearance Scale and Its Short Form in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life Study. J Rheumatol. 2015 Sep; 42(9):1624-30. PMID: 26034157; PMCID: PMC4809411.
    97. Bauer E, Lucier J, Furst DE. Brodalumab -an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis. Expert Opin Biol Ther. 2015 Jun; 15(6):883-93. PMID: 25985813.
      View in: PubMed
    98. Nurmohamed M, Bao Y, Signorovitch J, Trahey A, Mulani P, Furst DE. Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis. RMD Open. 2015; 1(1):e000080. PMID: 26535138; PMCID: PMC4612693.
    99. Volkmann ER, Furst DE. Management of Systemic Sclerosis-Related Skin Disease: A Review of Existing and Experimental Therapeutic Approaches. Rheum Dis Clin North Am. 2015 Aug; 41(3):399-417. PMID: 26210126.
      View in: PubMed
    100. Bartlett SJ, Bykerk VP, Cooksey R, Choy EH, Alten R, Christensen R, Furst DE, Guillemin F, Halls S, Hewlett S, Leong AL, Lyddiatt A, March L, Montie P, Orbai AM, Pohl C, Voshaar MS, Woodworth TG, Bingham CO. Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group Plenary. J Rheumatol. 2015 Nov; 42(11):2185-9. PMID: 25684764; PMCID: PMC4747421.
    101. Wallace B, Kafaja S, Furst DE, Berrocal VJ, Merkel PA, Seibold JR, Mayes MD, Khanna D. Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis. Rheumatology (Oxford). 2015 Aug; 54(8):1369-79. PMID: 25667436; PMCID: PMC4502336.
    102. Tashkin DP, Volkmann ER, Tseng CH, Kim HJ, Goldin J, Clements P, Furst D, Khanna D, Kleerup E, Roth MD, Elashoff R. Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. Ann Rheum Dis. 2016 Feb; 75(2):374-81. PMID: 25452309.
      View in: PubMed
    103. Salazar GA, Assassi S, Wigley F, Hummers L, Varga J, Hinchcliff M, Khanna D, Schiopu E, Phillips K, Furst DE, Steen V, Baron M, Hudson M, Taillefer SS, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, Simms RW, Silver RM, Frech TM, Fessler BJ, Molitor JA, Fritzler MJ, Segal BM, Al-Kassab F, Perry M, Yang J, Zamanian S, Reveille JD, Arnett FC, Pedroza C, Mayes MD. Antinuclear antibody-negative systemic sclerosis. Semin Arthritis Rheum. 2015 Jun; 44(6):680-6. PMID: 25578738.
      View in: PubMed
    104. Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barré E, Karyekar CS, Wong DA, Huizinga TW. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015 Jan; 74(1):19-26. PMID: 25367713; PMCID: PMC4283672.
    105. Wiese AB, Berrocal VJ, Furst DE, Seibold JR, Merkel PA, Mayes MD, Khanna D. Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis. Arthritis Care Res (Hoboken). 2014 Nov; 66(11):1731-9. PMID: 24692361; PMCID: PMC4511097.
    106. Dossing A, Tarp S, Furst DE, Gluud C, Beyene J, Hansen BB, Bliddal H, Christensen R. Interpreting trial results following use of different intention-to-treat approaches for preventing attrition bias: a meta-epidemiological study protocol. BMJ Open. 2014 Sep 26; 4(9):e005297. PMID: 25260368; PMCID: PMC4179424.
    107. Khanna D, Furst DE, Allanore Y, Bae S, Bodukam V, Clements PJ, Cutolo M, Czirjak L, Denton CP, Distler O, Walker UA, Matucci-Cerinic M, Müller-Ladner U, Seibold JR, Singh M, Tyndall A. Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. Rheumatology (Oxford). 2015 Jan; 54(1):144-51. PMID: 25125594; PMCID: PMC4269793.
    108. Kafaja S, Furst DE. Rheumatoid arthritis: are current research-based guidelines clinically relevant? J Rheumatol. 2014 Aug; 41(8):1569-70. PMID: 25086136.
      View in: PubMed
    109. Woodworth TG, Furst DE. Safety and feasibility of umbilical cord mesenchymal stem cells in treatment-refractory systemic lupus erythematosus nephritis: time for a double-blind placebo-controlled trial to determine efficacy. Arthritis Res Ther. 2014 Jul 30; 16(4):113. PMID: 25166210; PMCID: PMC4261567.
    110. Volkmann ER, Saggar R, Khanna D, Torres B, Flora A, Yoder L, Clements PJ, Elashoff RM, Ross DJ, Agrawal H, Borazan N, Furst DE, Saggar R. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease. Arthritis Rheumatol. 2014 Jul; 66(7):1900-8. PMID: 24729406.
      View in: PubMed
    111. Wells G, Beaton DE, Tugwell P, Boers M, Kirwan JR, Bingham CO, Boonen A, Brooks P, Conaghan PG, D'Agostino MA, Dougados M, Furst DE, Gossec L, Guillemin F, Helliwell P, Hewlett S, Kvien TK, Landewé RB, March L, Mease PJ, Ostergaard M, Simon L, Singh JA, Strand V, van der Heijde DM. Updating the OMERACT filter: discrimination and feasibility. J Rheumatol. 2014 May; 41(5):1005-10. PMID: 24692522.
      View in: PubMed
    112. Tugwell P, Boers M, D'Agostino MA, Beaton D, Boonen A, Bingham CO, Choy E, Conaghan PG, Dougados M, Duarte C, Furst DE, Guillemin F, Gossec L, Heiberg T, van der Heijde DM, Hewlett S, Kirwan JR, Kvien TK, Landewé RB, Mease PJ, Østergaard M, Simon L, Singh JA, Strand V, Wells G. Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validity. J Rheumatol. 2014 May; 41(5):1000-4. PMID: 24692531.
      View in: PubMed
    113. Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, Dasgupta B, Bryson J, Duncan B, Zhu W, Pitzalis C, Durez P, Kretsos K. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014 Sep; 73(9):1607-15. PMID: 24641941; PMCID: PMC4145439.
    114. Kirwan JR, Boers M, Hewlett S, Beaton D, Bingham CO, Choy E, Conaghan PG, D'Agostino MA, Dougados M, Furst DE, Guillemin F, Gossec L, van der Heijde DM, Kloppenburg M, Kvien TK, Landewé RB, Mackie SL, Matteson EL, Mease PJ, Merkel PA, Ostergaard M, Saketkoo LA, Simon L, Singh JA, Strand V, Tugwell P. Updating the OMERACT filter: core areas as a basis for defining core outcome sets. J Rheumatol. 2014 May; 41(5):994-9. PMID: 24634204; PMCID: PMC4217644.
    115. Hsu VM, Chung L, Hummers LK, Wigley F, Simms R, Bolster M, Silver R, Fischer A, Hinchcliff ME, Varga J, Goldberg AZ, Derk CT, Schiopu E, Khanna D, Shapiro LS, Domsic RT, Medsger T, Mayes MD, Furst D, Csuka ME, Molitor JA, Alkassab F, Steen VD. Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Semin Arthritis Rheum. 2014 Aug; 44(1):55-62. PMID: 24709277.
      View in: PubMed
    116. Chung L, Domsic RT, Lingala B, Alkassab F, Bolster M, Csuka ME, Derk C, Fischer A, Frech T, Furst DE, Gomberg-Maitland M, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TA, Molitor JA, Preston IR, Schiopu E, Shapiro L, Silver R, Simms R, Varga J, Gordon JK, Steen VD. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken). 2014 Mar; 66(3):489-95. PMID: 23983198.
      View in: PubMed
    117. Bykerk VP, Lie E, Bartlett SJ, Alten R, Boonen A, Christensen R, Furst DE, Hewlett S, Leong AL, Lyddiatt A, March L, May JE, Montie P, Orbai AM, Pohl C, Scholte Voshaar M, Woodworth T, Bingham CO, Choy EH. Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop. J Rheumatol. 2014 Apr; 41(4):799-809. PMID: 24584927; PMCID: PMC4365895.
    118. Kay J, Morgacheva O, Messing SP, Kremer JM, Greenberg JD, Reed GW, Gravallese EM, Furst DE. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res Ther. 2014 Feb 03; 16(1):R40. PMID: 24485007; PMCID: PMC3978994.
    119. Furst DE, Emery P. Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. Rheumatology (Oxford). 2014 Sep; 53(9):1560-9. PMID: 24402580; PMCID: PMC4135582.
    120. Mayes MD, Bossini-Castillo L, Gorlova O, Martin JE, Zhou X, Chen WV, Assassi S, Ying J, Tan FK, Arnett FC, Reveille JD, Guerra S, Teruel M, Carmona FD, Gregersen PK, Lee AT, López-Isac E, Ochoa E, Carreira P, Simeón CP, Castellví I, González-Gay MÁ, Zhernakova A, Padyukov L, Alarcón-Riquelme M, Wijmenga C, Brown M, Beretta L, Riemekasten G, Witte T, Hunzelmann N, Kreuter A, Distler JH, Voskuyl AE, Schuerwegh AJ, Hesselstrand R, Nordin A, Airó P, Lunardi C, Shiels P, van Laar JM, Herrick A, Worthington J, Denton C, Wigley FM, Hummers LK, Varga J, Hinchcliff ME, Baron M, Hudson M, Pope JE, Furst DE, Khanna D, Phillips K, Schiopu E, Segal BM, Molitor JA, Silver RM, Steen VD, Simms RW, Lafyatis RA, Fessler BJ, Frech TM, Alkassab F, Docherty P, Kaminska E, Khalidi N, Jones HN, Markland J, Robinson D, Broen J, Radstake TR, Fonseca C, Koeleman BP, Martin J. Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. Am J Hum Genet. 2014 Jan 02; 94(1):47-61. PMID: 24387989; PMCID: PMC3882906.
    121. Schiopu E, Au KM, McMahon MA, Kaplan MJ, Divekar A, Singh RR, Furst DE, Clements PJ, Ragvendra N, Zhao W, Maranian P, Khanna D. Prevalence of subclinical atherosclerosis is increased in systemic sclerosis and is associated with serum proteins: a cross-sectional, controlled study of carotid ultrasound. Rheumatology (Oxford). 2014 Apr; 53(4):704-13. PMID: 24357811; PMCID: PMC4042927.
    122. Furst DE, Mandell B, Calabrese LH, Cather JC, Clauw DJ, Deodhar A, Kremer JM, Lewiecki EM, McMahon M, Ritchlin CT. Proceedings of the 5th annual perspectives in rheumatic diseases. Semin Arthritis Rheum. 2013 Dec; 43(3):416-9. PMID: 24326035.
      View in: PubMed
    123. Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE, Hachulla E, Humbert M, Langleben D, Mathai SC, Saggar R, Visovatti S, Altorok N, Townsend W, FitzGerald J, McLaughlin VV. Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum. 2013 Dec; 65(12):3194-201. PMID: 24022584; PMCID: PMC3883571.
    124. Navarro G, Taroumian S, Barroso N, Duan L, Furst D. Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums. Semin Arthritis Rheum. 2014 Feb; 43(4):458-69. PMID: 24262929.
      View in: PubMed
    125. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Müller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Ellen Csuka M, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013 Nov; 72(11):1747-55. PMID: 24092682.
      View in: PubMed
    126. Assassi S, Wu M, Tan FK, Chang J, Graham TA, Furst DE, Khanna D, Charles J, Ferguson EC, Feghali-Bostwick C, Mayes MD. Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis. Arthritis Rheum. 2013 Nov; 65(11):2917-27. PMID: 23897225; PMCID: PMC3898704.
    127. Hudson M, Baron M, Tatibouet S, Furst DE, Khanna D. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum. 2014 Apr; 43(5):666-72. PMID: 24176729.
      View in: PubMed
    128. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Müller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013 Nov; 65(11):2737-47. PMID: 24122180; PMCID: PMC3930146.
    129. Volkmann ER, Rezai S, Tarp S, Woodworth TG, Furst DE. We still don't know how to taper glucocorticoids in rheumatoid arthritis, and we can do better. J Rheumatol. 2013 Oct; 40(10):1646-9. PMID: 24085754.
      View in: PubMed
    130. Kwakkenbos L, Jewett LR, Baron M, Bartlett SJ, Furst D, Gottesman K, Khanna D, Malcarne VL, Mayes MD, Mouthon L, Poiraudeau S, Sauve M, Nielson WR, Poole JL, Assassi S, Boutron I, Ells C, van den Ende CH, Hudson M, Impens A, Körner A, Leite C, Costa Maia A, Mendelson C, Pope J, Steele RJ, Suarez-Almazor ME, Ahmed S, Coronado-Montoya S, Delisle VC, Gholizadeh S, Jang Y, Levis B, Milette K, Mills SD, Razykov I, Fox RS, Thombs BD. The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context. BMJ Open. 2013 Aug 07; 3(8). PMID: 23929922; PMCID: PMC3740254.
    131. Bae S, Allanore Y, Furst DE, Bodukam V, Coustet B, Morgaceva O, Maranian P, Khanna D. Associations between a scleroderma-specific gastrointestinal instrument and objective tests of upper gastrointestinal involvements in systemic sclerosis. Clin Exp Rheumatol. 2013 Mar-Apr; 31(2 Suppl 76):57-63. PMID: 23910611.
      View in: PubMed
    132. Lie E, Woodworth TG, Christensen R, Kvien TK, Bykerk V, Furst DE, Bingham CO, Choy EH. Validation of OMERACT preliminary rheumatoid arthritis flare domains in the NOR-DMARD study. Ann Rheum Dis. 2014 Oct; 73(10):1781-7. PMID: 23852690.
      View in: PubMed
    133. Furst DE, Kay J, Wasko MC, Keystone E, Kavanaugh A, Deodhar A, Murphy FT, Magnus JH, Hsia EC, Hsu B, Xu S, Rahman MU, Doyle MK. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Rheumatology (Oxford). 2013 Oct; 52(10):1845-55. PMID: 23838027; PMCID: PMC3775295.
    134. Ranganath VK, Maranian P, Elashoff DA, Woodworth T, Khanna D, Hahn T, Sarkisian C, Kremer JM, Furst DE, Paulus HE. Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. Rheumatology (Oxford). 2013 Oct; 52(10):1809-17. PMID: 23813577; PMCID: PMC3775293.
    135. Singh JA, Saag KG, Furst D. Reply: To PMID 22473917. Arthritis Care Res (Hoboken). 2013 May; 65(5):832-3. PMID: 23097242.
      View in: PubMed
    136. Amarilyo G, Woo JM, Furst DE, Hoffman OL, Eyal R, Piao C, Parker DS, McCurdy DK. Publication outcomes of abstracts presented at an American College of Rheumatology/Association of Rheumatology Health Professionals annual scientific meeting. Arthritis Care Res (Hoboken). 2013 Apr; 65(4):622-9. PMID: 23045154.
      View in: PubMed
    137. Furst DE, Fleischman R, Kalden J, Kavanaugh A, Sieper J, Mease P, Smolen J, Breedveld F. Documentation of off-label use of biologics in Rheumatoid Arthritis. Ann Rheum Dis. 2013 Apr; 72 Suppl 2:ii35-51. PMID: 23532442.
      View in: PubMed
    138. Furst DE, Keystone EC, So AK, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Rubbert-Roth A, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop KL. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis. 2013 Apr; 72 Suppl 2:ii2-34. PMID: 23532441.
      View in: PubMed
    139. Hung EW, Mayes MD, Sharif R, Assassi S, Machicao VI, Hosing C, St Clair EW, Furst DE, Khanna D, Forman S, Mineishi S, Phillips K, Seibold JR, Bredeson C, Csuka ME, Nash RA, Wener MH, Simms R, Ballen K, Leclercq S, Storek J, Goldmuntz E, Welch B, Keyes-Elstein L, Castina S, Crofford LJ, Mcsweeney P, Sullivan KM. Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial. J Rheumatol. 2013 Apr; 40(4):455-60. PMID: 23418384; PMCID: PMC3652008.
    140. Doyle MK, Rahman MU, Frederick B, Birbara CA, de Vries D, Toedter G, Wu X, Chen D, Ranganath VK, Westerman ME, Furst DE. Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial. Rheumatology (Oxford). 2013 Jul; 52(7):1214-9. PMID: 23418046.
      View in: PubMed
    141. Amarilyo G, Amarlilyo G, Rullo OJ, McCurdy DK, Woo JM, Furst DE. Folate usage in MTX-treated juvenile idiopathic arthritis (JIA) patients is inconsistent and highly variable. Rheumatol Int. 2013 Sep; 33(9):2437-40. PMID: 23400770.
      View in: PubMed
    142. Furst DE, Clarke A, Fernandes AW, Bancroft T, Gajria K, Greth W, Iorga SR. Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured population. J Med Econ. 2013; 16(4):500-9. PMID: 23363329.
      View in: PubMed
    143. Avouac J, Huscher D, Furst DE, Opitz CF, Distler O, Allanore Y. Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis. Ann Rheum Dis. 2014 Jan; 73(1):191-7. PMID: 23349131.
      View in: PubMed
    144. Jawaheer D, Messing S, Reed G, Ranganath VK, Kremer JM, Louie JS, Khanna D, Greenberg JD, Furst DE. Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2012 Dec; 64(12):1811-8. PMID: 22730408; PMCID: PMC3604992.
    145. van Vollenhoven RF, Emery P, Bingham CO, Keystone EC, Fleischmann RM, Furst DE, Tyson N, Collinson N, Lehane PB. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013 Sep 01; 72(9):1496-502. PMID: 23136242; PMCID: PMC3756452.
    146. Tarp S, Bartels EM, Bliddal H, Furst DE, Boers M, Danneskiold-Samsøe B, Rasmussen M, Christensen R. Effect of nonsteroidal antiinflammatory drugs on the C-reactive protein level in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum. 2012 Nov; 64(11):3511-21. PMID: 22833186.
      View in: PubMed
    147. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Lioté F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012 Oct; 64(10):1431-46. PMID: 23024028; PMCID: PMC3683400.
    148. Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Lioté F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012 Oct; 64(10):1447-61. PMID: 23024029; PMCID: PMC3662546.
    149. Furst DE, Fernandes AW, Iorga SR, Greth W, Bancroft T. Annual medical costs and healthcare resource use in patients with systemic sclerosis in an insured population. J Rheumatol. 2012 Dec; 39(12):2303-9. PMID: 23027885.
      View in: PubMed
    150. Furst DE, Amato AA, Iorga SR, Bancroft T, Fernandes AW. Medical costs and health-care resource use in patients with inflammatory myopathies in an insured population. Muscle Nerve. 2012 Oct; 46(4):496-505. PMID: 22987689.
      View in: PubMed
    151. Townes SV, Furst DE, Thenkondar A. The impact of tocilizumab on physical function and quality of life in patients with rheumatoid arthritis: a systematic literature review and interpretation. Open Access Rheumatol. 2012; 4:87-92. PMID: 27790016.
      View in: PubMed
    152. Kim PS, Ho GY, Prete PE, Furst DE. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. Arthritis Care Res (Hoboken). 2012 Aug; 64(8):1265-8. PMID: 22392695.
      View in: PubMed
    153. Massardo L, Pons-Estel BA, Wojdyla D, Cardiel MH, Galarza-Maldonado CM, Sacnun MP, Soriano ER, Laurindo IM, Acevedo-Vásquez EM, Caballero-Uribe CV, Padilla O, Guibert-Toledano ZM, da Mota LM, Montufar RA, Lino-Pérez L, Díaz-Coto JF, Achurra-Castillo AF, Hernández JA, Esteva-Spinetti MH, Ramírez LA, Pineda C, Furst DE. Early rheumatoid arthritis in Latin America: low socioeconomic status related to high disease activity at baseline. Arthritis Care Res (Hoboken). 2012 Aug; 64(8):1135-43. PMID: 22505270.
      View in: PubMed
    154. Morgacheva O, Furst DE. Women are from venus, men are from Mars: do gender differences also apply to rheumatoid arthritis activity and treatment responses? J Clin Rheumatol. 2012 Aug; 18(5):259-60. PMID: 22832285.
      View in: PubMed
    155. Bartlett SJ, Hewlett S, Bingham CO, Woodworth TG, Alten R, Pohl C, Choy EH, Sanderson T, Boonen A, Bykerk V, Leong AL, Strand V, Furst DE, Christensen R. Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. Ann Rheum Dis. 2012 Nov; 71(11):1855-60. PMID: 22772326.
      View in: PubMed
    156. Agrawal H, Hay MC, Volkmann ER, Maranian P, Khanna D, Furst DE. Satisfaction and access to clinical care in a rheumatology clinic at a large urban medical center. J Clin Rheumatol. 2012 Jun; 18(4):209-11. PMID: 22647867.
      View in: PubMed
    157. Chung L, Denton CP, Distler O, Furst DE, Khanna D, Merkel PA. Clinical trial design in scleroderma: where are we and where do we go next? Clin Exp Rheumatol. 2012 Mar-Apr; 30(2 Suppl 71):S97-102. PMID: 22691217.
      View in: PubMed
    158. Thombs BD, Jewett LR, Assassi S, Baron M, Bartlett SJ, Maia AC, El-Baalbaki G, Furst DE, Gottesman K, Haythornthwaite JA, Hudson M, Impens A, Korner A, Leite C, Mayes MD, Malcarne VL, Motivala SJ, Mouthon L, Nielson WR, Plante D, Poiraudeau S, Poole JL, Pope J, Sauve M, Steele RJ, Suarez-Almazor ME, Taillefer S, van den Ende CH, Arthurs E, Bassel M, Delisle V, Milette K, Leavens A, Razykov I, Khanna D. New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN). Clin Exp Rheumatol. 2012 Mar-Apr; 30(2 Suppl 71):S23-9. PMID: 22244687; PMCID: PMC3925434.
    159. van der Heijde D, Keystone EC, Curtis JR, Landewé RB, Schiff MH, Khanna D, Kvien TK, Ionescu L, Gervitz LM, Davies OR, Luijtens K, Furst DE. Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial. J Rheumatol. 2012 Jul; 39(7):1326-33. PMID: 22589265.
      View in: PubMed
    160. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012 May; 64(5):625-39. PMID: 22473917; PMCID: PMC4081542.
    161. Furst DE, Amato AA, Iorga SR, Gajria K, Fernandes AW. Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve. 2012 May; 45(5):676-83. PMID: 22499094.
      View in: PubMed
    162. Furst DE, Mandell B. Perspectives in Rheumatoid Abstracts from 2011 meeting selected proceedings of the 4(th) Annual Perspectives in Rheumatic Diseases 2011. Semin Arthritis Rheum. 2012 Apr; 41(5):737-9. PMID: 22483654.
      View in: PubMed
    163. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis. 2012 Apr; 71 Suppl 2:i2-45. PMID: 22460137.
      View in: PubMed
    164. Avouac J, Clements PJ, Khanna D, Furst DE, Allanore Y. Articular involvement in systemic sclerosis. Rheumatology (Oxford). 2012 Aug; 51(8):1347-56. PMID: 22467084.
      View in: PubMed
    165. Sharif R, Mayes MD, Tan FK, Gorlova OY, Hummers LK, Shah AA, Furst DE, Khanna D, Martin J, Bossini-Castillo L, Gonzalez EB, Ying J, Draeger HT, Agarwal SK, Reveille JD, Arnett FC, Wigley FM, Assassi S. IRF5 polymorphism predicts prognosis in patients with systemic sclerosis. Ann Rheum Dis. 2012 Jul; 71(7):1197-202. PMID: 22440820.
      View in: PubMed
    166. Fransen J, Johnson SR, van den Hoogen F, Baron M, Allanore Y, Carreira PE, Czirják L, Denton CP, Distler O, Furst DE, Gabrielli A, Herrick A, Inanc M, Kahaleh B, Kowal-Bielecka O, Medsger TA, Mueller-Ladner U, Riemekasten G, Sierakowski S, Valentini G, Veale D, Vonk MC, Walker U, Chung L, Clements PJ, Collier DH, Csuka ME, Jimenez S, Merkel PA, Seibold JR, Silver R, Steen V, Tyndall A, Matucci-Cerinic M, Pope JE, Khanna D. Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care Res (Hoboken). 2012 Mar; 64(3):351-7. PMID: 22052558; PMCID: PMC3288452.
    167. Furst DE, Fernandes AW, Iorga SR, Greth W, Bancroft T. Epidemiology of systemic sclerosis in a large US managed care population. J Rheumatol. 2012 Apr; 39(4):784-6. PMID: 22382343.
      View in: PubMed
    168. Harrold LR, Harrington JT, Curtis JR, Furst DE, Bentley MJ, Shan Y, Reed G, Kremer J, Greenberg JD. Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations. Arthritis Rheum. 2012 Mar; 64(3):630-8. PMID: 21953645; PMCID: PMC3253907.
    169. Bae S, Saggar R, Bolster MB, Chung L, Csuka ME, Derk C, Domsic R, Fischer A, Frech T, Goldberg A, Hinchcliff M, Hsu V, Hummers L, Schiopu E, Mayes MD, McLaughlin V, Molitor J, Naz N, Furst DE, Maranian P, Steen V, Khanna D. Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. Ann Rheum Dis. 2012 Aug; 71(8):1335-42. PMID: 22307943; PMCID: PMC3398226.
    170. Singh MK, Clements PJ, Furst DE, Maranian P, Khanna D. Work productivity in scleroderma: analysis from the University of California, Los Angeles scleroderma quality of life study. Arthritis Care Res (Hoboken). 2012 Feb; 64(2):176-83. PMID: 22012885; PMCID: PMC3266976.
    171. Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, Dehoratius R, Kishimoto M, Kremer JM. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis. 2012 Jul; 71(7):1134-42. PMID: 22294625.
      View in: PubMed
    172. Sullivan KM, Wigley FM, Denton CP, van Laar JM, Furst DE. Haemopoietic stem-cell transplantation for systemic sclerosis. Lancet. 2012 Jan 21; 379(9812):219; author reply 219-20. PMID: 22265628.
      View in: PubMed
    173. Clements PJ, Allanore Y, Khanna D, Singh M, Furst DE. Arthritis in systemic sclerosis: systematic review of the literature and suggestions for the performance of future clinical trials in systemic sclerosis arthritis. Semin Arthritis Rheum. 2012 Jun; 41(6):801-14. PMID: 22177105.
      View in: PubMed
    174. Solgi G, Furst D, Mytilineos J, Pourmand G, Amirzargar AA. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA. Transpl Immunol. 2012 Mar; 26(2-3):81-7. PMID: 22182633.
      View in: PubMed
    175. Khanna D, Saggar R, Mayes MD, Abtin F, Clements PJ, Maranian P, Assassi S, Saggar R, Singh RR, Furst DE. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum. 2011 Nov; 63(11):3540-6. PMID: 21769849; PMCID: PMC3205223.
    176. Khanna D, Maranian P, Rothrock N, Cella D, Gershon R, Khanna PP, Spiegel B, Furst DE, Clements PJ, Bechtel A, Hays RD. Feasibility and construct validity of PROMIS and "legacy" instruments in an academic scleroderma clinic. Value Health. 2012 Jan; 15(1):128-34. PMID: 22264980; PMCID: PMC3457915.
    177. Kowal-Bielecka O, Avouac J, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE, Distler O. Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). J Rheumatol. 2011 Nov; 38(11):2419-27. PMID: 21965635.
      View in: PubMed
    178. Khanna D, Tseng CH, Farmani N, Steen V, Furst DE, Clements PJ, Roth MD, Goldin J, Elashoff R, Seibold JR, Saggar R, Tashkin DP. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum. 2011 Oct; 63(10):3078-85. PMID: 21618205; PMCID: PMC3183128.
    179. Ozturk MA, Kanbay M, Kasapoglu B, Onat AM, Guz G, Furst DE, Ben-Chetrit E. Therapeutic approach to familial Mediterranean fever: a review update. Clin Exp Rheumatol. 2011 Jul-Aug; 29(4 Suppl 67):S77-86. PMID: 21968242.
      View in: PubMed
    180. Divekar AA, Khanna D, Abtin F, Maranian P, Saggar R, Saggar R, Furst DE, Singh RR. Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis. Clin Immunol. 2011 Dec; 141(3):293-303. PMID: 22015344; PMCID: PMC3221795.
    181. Roth MD, Tseng CH, Clements PJ, Furst DE, Tashkin DP, Goldin JG, Khanna D, Kleerup EC, Li N, Elashoff D, Elashoff RM. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum. 2011 Sep; 63(9):2797-808. PMID: 21547897; PMCID: PMC3910296.
    182. Kirwan JR, Boonen A, Harrison MJ, Hewlett SE, Wells GA, Singh JA, Furst DE, Dworkin RH. OMERACT 10 Patient Perspective Virtual Campus: valuing health; measuring outcomes in rheumatoid arthritis fatigue, RA sleep, arthroplasty, and systemic sclerosis; and clinical significance of changes in health. J Rheumatol. 2011 Aug; 38(8):1728-34. PMID: 21807793.
      View in: PubMed
    183. Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011 Aug; 63(8):2226-37. PMID: 21480191.
      View in: PubMed
    184. Alten R, Pohl C, Choy EH, Christensen R, Furst DE, Hewlett SE, Leong A, May JE, Sanderson TC, Strand V, Woodworth TG, Bingham CO. Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group. J Rheumatol. 2011 Aug; 38(8):1745-50. PMID: 21807796.
      View in: PubMed
    185. Bingham CO, Alten R, Bartlett SJ, Bykerk VP, Brooks PM, Choy E, Christensen R, Furst DE, Hewlett SE, Leong A, May JE, Montie P, Pohl C, Sanderson TC, Strand V, Woodworth TG. Identifying preliminary domains to detect and measure rheumatoid arthritis flares: report of the OMERACT 10 RA Flare Workshop. J Rheumatol. 2011 Aug; 38(8):1751-8. PMID: 21807797.
      View in: PubMed
    186. Khanna D, Furst DE, Maranian P, Seibold JR, Impens A, Mayes MD, Clements PJ, Getzug T, Hays RD. Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. J Rheumatol. 2011 Sep; 38(9):1920-4. PMID: 21724699; PMCID: PMC3368014.
    187. Denton CP, Avouac J, Behrens F, Furst DE, Foeldvari I, Humbert M, Huscher D, Kowal-Bielecka O, Matucci-Cerinic M, Nash P, Opitz CF, Pittrow D, Rubin LJ, Seibold JR, Distler O. Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed. Arthritis Res Ther. 2011 Jun 20; 13(3):114. PMID: 21699746; PMCID: PMC3218892.
    188. Furst DE, Venkatraman MM, McGann M, Manohar PR, Booth-LaForce C, Sarin R, Sekar PG, Raveendran KG, Mahapatra A, Gopinath J, Kumar PR. Double-blind, randomized, controlled, pilot study comparing classic ayurvedic medicine, methotrexate, and their combination in rheumatoid arthritis. J Clin Rheumatol. 2011 Jun; 17(4):185-92. PMID: 21617554.
      View in: PubMed
    189. Furst DE, Pangan AL, Harrold LR, Chang H, Reed G, Kremer JM, Greenberg JD. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care Res (Hoboken). 2011 Jun; 63(6):856-64. PMID: 21337725; PMCID: PMC4559141.
    190. Khanna D, Kowal-Bielecka O, Khanna PP, Lapinska A, Asch SM, Wenger N, Brown KK, Clements PJ, Getzug T, Mayes MD, Medsger TA, Oudiz R, Simms R, Steen V, Maranian P, Furst DE. Quality indicator set for systemic sclerosis. Clin Exp Rheumatol. 2011 Mar-Apr; 29(2 Suppl 65):S33-9. PMID: 21586216; PMCID: PMC3887520.
    191. Sharif R, Fritzler MJ, Mayes MD, Gonzalez EB, McNearney TA, Draeger H, Baron M, Furst DE, Khanna DK, del Junco DJ, Molitor JA, Schiopu E, Phillips K, Seibold JR, Silver RM, Simms RW, Perry M, Rojo C, Charles J, Zhou X, Agarwal SK, Reveille JD, Assassi S, Arnett FC. Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis. J Rheumatol. 2011 Aug; 38(8):1622-30. PMID: 21572159.
      View in: PubMed
    192. Furst DE, Tseng CH, Clements PJ, Strange C, Tashkin DP, Roth MD, Khanna D, Li N, Elashoff R, Schraufnagel DE. Adverse events during the Scleroderma Lung Study. Am J Med. 2011 May; 124(5):459-67. PMID: 21531236.
      View in: PubMed
    193. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewé R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011 Mar; 70(3):404-13. PMID: 21292833.
      View in: PubMed
    194. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewé R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011 Mar; 63(3):573-86. PMID: 21294106; PMCID: PMC3115717.
    195. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis. 2011 Mar; 70 Suppl 1:i2-36. PMID: 21339216.
      View in: PubMed
    196. Keystone EC, Curtis JR, Fleischmann RM, Furst DE, Khanna D, Smolen JS, Mease PJ, Schiff MH, Coteur G, Davies O, Combe B. Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial. J Rheumatol. 2011 Jun; 38(6):990-6. PMID: 21362764.
      View in: PubMed
    197. Frech T, Hays RD, Maranian P, Clements PJ, Furst DE, Khanna D. Prevalence and correlates of sleep disturbance in systemic sclerosis--results from the UCLA scleroderma quality of life study. Rheumatology (Oxford). 2011 Jul; 50(7):1280-7. PMID: 21324979; PMCID: PMC3116211.
    198. Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, Furst DE. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011 May; 70(5):785-91. PMID: 21288960.
      View in: PubMed
    199. Au K, Mayes MD, Maranian P, Clements PJ, Khanna D, Steen VD, Tashkin D, Roth MD, Elashoff R, Furst DE. Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study. Arthritis Care Res (Hoboken). 2010 Dec; 62(12):1772-8. PMID: 20740615; PMCID: PMC2994974.
    200. Saggar R, Khanna D, Furst DE, Shapiro S, Maranian P, Belperio JA, Chauhan N, Clements P, Gorn A, Weigt SS, Ross D, Lynch JP, Saggar R. Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities. Arthritis Rheum. 2010 Dec; 62(12):3741-50. PMID: 20722025.
      View in: PubMed
    201. Furst DE, Tyndall A, Matucci-Cerinic M. First Systemic Sclerosis World Congress. Clin Exp Rheumatol. 2010 Sep-Oct; 28(5 Suppl 62):S1-2. PMID: 21050536.
      View in: PubMed
    202. Tan W, Wu H, Zhao J, Derber LA, Lee DM, Shadick NA, Conn DL, Smith EA, Gersuk VH, Nepom GT, Moreland LW, Furst DE, Thompson SD, Jonas BL, Holers VM, Glass DN, Chen PP, Bridges SL, Weinblatt ME, Paulus HE, Tsao BP. A functional RANKL polymorphism associated with younger age at onset of rheumatoid arthritis. Arthritis Rheum. 2010 Oct; 62(10):2864-75. PMID: 20533289; PMCID: PMC2944013.
    203. Nashid M, Khanna PP, Furst DE, Clements PJ, Maranian P, Seibold J, Postlethwaite AE, Louie JS, Mayes MD, Agrawal H, Khanna D. Gender and ethnicity differences in patients with diffuse systemic sclerosis--analysis from three large randomized clinical trials. Rheumatology (Oxford). 2011 Feb; 50(2):335-42. PMID: 20889574; PMCID: PMC3107588.
    204. Bodukam V, Hays RD, Maranian P, Furst DE, Seibold JR, Impens A, Mayes MD, Clements PJ, Khanna D. Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis. Rheumatology (Oxford). 2011 Feb; 50(2):330-4. PMID: 20884655; PMCID: PMC3021949.
    205. Hudson M, Baron M, Lo E, Weinfeld J, Furst DE, Khanna D. An International, Web-Based, Prospective Cohort Study to Determine Whether the Use of ACE Inhibitors prior to the Onset of Scleroderma Renal Crisis Is Associated with Worse Outcomes-Methodology and Preliminary Results. Int J Rheumatol. 2010; 2010. PMID: 20936135; PMCID: PMC2947816.
    206. Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, Wigley FM, Black CM, Fessler BJ, Merkel PA, Pope JE, Sweiss NJ, Doyle MK, Hellmich B, Medsger TA, Morganti A, Kramer F, Korn JH, Seibold JR. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011 Jan; 70(1):32-8. PMID: 20805294; PMCID: PMC3002766.
    207. Furst DE, Venkatraman MM, Krishna Swamy BG, McGann M, Booth-Laforce C, Ram Manohar P, Sarin R, Mahapatra A, Krishna Kumar PR. Well controlled, double-blind, placebo-controlled trials of classical Ayurvedic treatment are possible in rheumatoid arthritis. Ann Rheum Dis. 2011 Feb; 70(2):392-3. PMID: 20736391.
      View in: PubMed
    208. Hosing C, Nash R, McSweeney P, Mineishi S, Seibold J, Griffith LM, Shulman H, Goldmuntz E, Mayes M, Parikh CR, Crofford L, Keyes-Elstein L, Furst D, Steen V, Sullivan KM. Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States. Biol Blood Marrow Transplant. 2011 May; 17(5):674-81. PMID: 20708086; PMCID: PMC3012135.
    209. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, Curtis JR, Furst DE, McMahon M, Patkar NM, Volkmann E, Saag KG. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010 Nov; 62(11):1515-26. PMID: 20662044.
      View in: PubMed
    210. Khanna D, Brown KK, Clements PJ, Elashoff R, Furst DE, Goldin J, Seibold JR, Silver RM, Tashkin DP, Wells AU. Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials. Clin Exp Rheumatol. 2010 Mar-Apr; 28(2 Suppl 58):S55-62. PMID: 20576216.
      View in: PubMed
    211. Furst DE. Development of TNF inhibitor therapies for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2010 May-Jun; 28(3 Suppl 59):S5-12. PMID: 20576219.
      View in: PubMed
    212. Huscher D, Pittrow D, Distler O, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Kowal-Bielecka O, Avouac J, Behrens F, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE. Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis. Clin Exp Rheumatol. 2010 Mar-Apr; 28(2 Suppl 58):S47-52. PMID: 20576214.
      View in: PubMed
    213. Sawitzke AD, Shi H, Finco MF, Dunlop DD, Harris CL, Singer NG, Bradley JD, Silver D, Jackson CG, Lane NE, Oddis CV, Wolfe F, Lisse J, Furst DE, Bingham CO, Reda DJ, Moskowitz RW, Williams HJ, Clegg DO. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis. 2010 Aug; 69(8):1459-64. PMID: 20525840.
      View in: PubMed
    214. Avouac J, Kowal-Bielecka O, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Distler O, Furst DE. Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. Ann Rheum Dis. 2010 Jul; 69(7):1360-3. PMID: 20472586.
      View in: PubMed
    215. Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, Anofrei A, Reed G, Calabrese L, Hooper M, Baumgartner S, Furst DE. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis. 2010 Sep; 69(9):1612-7. PMID: 20448284.
      View in: PubMed
    216. Khanna D, Seibold JR, Wells A, Distler O, Allanore Y, Denton C, Furst DE. Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design. Curr Rheumatol Rev. 2010 May 01; 6(2):138-144. PMID: 20676227.
      View in: PubMed
    217. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010 Apr; 62(4):1060-8. PMID: 20131255.
      View in: PubMed
    218. Storage SS, Agrawal H, Furst DE. Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. Korean J Intern Med. 2010 Mar; 25(1):1-17. PMID: 20195397; PMCID: PMC2829405.
    219. Khanna PP, Furst DE, Clements PJ, Maranian P, Indulkar L, Khanna D. Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial. Rheumatology (Oxford). 2010 May; 49(5):955-9. PMID: 20144926; PMCID: PMC2909791.
    220. Weng HH, Ranganath VK, Khanna D, Oh M, Furst DE, Park GS, Elashoff DA, Sharp JT, Gold RH, Peter JB, Paulus HE. Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritis. J Rheumatol. 2010 Mar; 37(3):550-7. PMID: 20110517; PMCID: PMC3413376.
    221. van Vollenhoven RF, Emery P, Bingham CO, Keystone EC, Fleischmann R, Furst DE, Macey K, Sweetser M, Kelman A, Rao R. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010 Mar; 37(3):558-67. PMID: 20110520.
      View in: PubMed
    222. Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Braun J, Bresnihan B, Burmester GR, De Benedetti F, Dörner T, Emery P, Gibofsky A, Kavanaugh A, Kirkham B, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH, Winthrop K. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis. 2010 Jan; 69 Suppl 1:i2-29. PMID: 19995740.
      View in: PubMed
    223. Kowal-Bielecka O, Avouac J, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE, Distler O. Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group. J Rheumatol. 2010 Jan; 37(1):105-15. PMID: 19955042.
      View in: PubMed
    224. Su TI, Khanna D, Furst DE, Danovitch G, Burger C, Maranian P, Clements PJ. Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study. Arthritis Rheum. 2009 Dec; 60(12):3821-30. PMID: 19950289; PMCID: PMC2841149.
    225. Goldin J, Elashoff R, Kim HJ, Yan X, Lynch D, Strollo D, Roth MD, Clements P, Furst DE, Khanna D, Vasunilashorn S, Li G, Tashkin DP. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest. 2009 Nov; 136(5):1333-1340. PMID: 19892673; PMCID: PMC2773360.
    226. Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, Elashoff D, Park G, McMahon M, Paulus HE, Fogelman AM, Reddy ST. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum. 2009 Oct; 60(10):2870-9. PMID: 19790070; PMCID: PMC2828490.
    227. Khanna D, Distler O, Avouac J, Behrens F, Clements PJ, Denton C, Foeldvari I, Giannini E, Huscher D, Kowal-Bielecka O, Lovell D, Matucci-Cerinic M, Mayes M, Merkel PA, Nash P, Opitz CF, Pittrow D, Rubin L, Seibold JR, Steen V, Strand CV, Tugwell PS, Varga J, Zink A, Furst DE. Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). J Rheumatol. 2009 Oct; 36(10):2356-61. PMID: 19820225.
      View in: PubMed
    228. Merz EL, Malcarne VL, Hansdottir I, Furst DE, Clements PJ, Weisman MH. A longitudinal analysis of humor coping and quality of life in systemic sclerosis. Psychol Health Med. 2009 Oct; 14(5):553-66. PMID: 19844834.
      View in: PubMed
    229. Khanna D, Tseng CH, Furst DE, Clements PJ, Elashoff R, Roth M, Elashoff D, Tashkin DP. Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study. Rheumatology (Oxford). 2009 Dec; 48(12):1537-40. PMID: 19776222; PMCID: PMC2777487.
    230. Khanna D, Hays RD, Maranian P, Seibold JR, Impens A, Mayes MD, Clements PJ, Getzug T, Fathi N, Bechtel A, Furst DE. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum. 2009 Sep 15; 61(9):1257-63. PMID: 19714600; PMCID: PMC2767193.
    231. Bingham CO, Pohl C, Woodworth TG, Hewlett SE, May JE, Rahman MU, Witter JP, Furst DE, Strand CV, Boers M, Alten RE. Developing a standardized definition for disease "flare" in rheumatoid arthritis (OMERACT 9 Special Interest Group). J Rheumatol. 2009 Oct; 36(10):2335-41. PMID: 19684147.
      View in: PubMed
    232. Amjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, Khanna PP, Khanna D. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. Arthritis Rheum. 2009 Aug; 60(8):2490-8. PMID: 19644851; PMCID: PMC2725229.
    233. Holmberg LA, Furst DE, McSweeney PA, Nash RA. Thymoglobulin and cyclophosphamide as treatment for diffuse cutaneous systemic sclerosis. J Rheumatol. 2009 Aug; 36(8):1839. PMID: 19671826.
      View in: PubMed
    234. Kaldas M, Khanna PP, Furst DE, Clements PJ, Kee Wong W, Seibold JR, Postlethwaite AE, Khanna D. Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials. Rheumatology (Oxford). 2009 Sep; 48(9):1143-6. PMID: 19605370; PMCID: PMC2734267.
    235. Furst DE, Chang H, Greenberg JD, Ranganath VK, Reed G, Ozturk ZE, Kremer JM. Prevalence of low hemoglobin levels and associations with other disease parameters in rheumatoid arthritis patients: evidence from the CORRONA registry. Clin Exp Rheumatol. 2009 Jul-Aug; 27(4):560-6. PMID: 19772785.
      View in: PubMed
    236. Mundwiler ML, Maranian P, Brown DH, Silverman JM, Wallace D, Khanna D, Louie J, Furst DE, Weisman MH. The utility of MRI in predicting radiographic erosions in the metatarsophalangeal joints of the rheumatoid foot: a prospective longitudinal cohort study. Arthritis Res Ther. 2009; 11(3):R94. PMID: 19545417; PMCID: PMC2714150.
    237. Malaviya AN, Kapoor S, Garg S, Rawat R, Shankar S, Nagpal S, Khanna D, Furst DE. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report. J Rheumatol. 2009 Jul; 36(7):1414-20. PMID: 19487263.
      View in: PubMed
    238. Hunter AM, Leuchter AF, Cook IA, Abrams M, Siegman BE, Furst DE, Chappell AS. Brain functional changes and duloxetine treatment response in fibromyalgia: a pilot study. Pain Med. 2009 May-Jun; 10(4):730-8. PMID: 19453962.
      View in: PubMed
    239. Amjadi SS, Maranian PM, Paulus HE, Kaplan RM, Ranganath VK, Furst DE, Khanna PP, Khanna D. Validating and assessing the sensitivity of the Health Assessment Questionnaire-Disability Index-derived Short Form-6D in patients with early aggressive rheumatoid arthritis. J Rheumatol. 2009 Jun; 36(6):1150-7. PMID: 19369459; PMCID: PMC2880525.
    240. Khanna D, Clements PJ, Furst DE, Korn JH, Ellman M, Rothfield N, Wigley FM, Moreland LW, Silver R, Kim YH, Steen VD, Firestein GS, Kavanaugh AF, Weisman M, Mayes MD, Collier D, Csuka ME, Simms R, Merkel PA, Medsger TA, Sanders ME, Maranian P, Seibold JR. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009 Apr; 60(4):1102-11. PMID: 19333948; PMCID: PMC3711466.
    241. Au K, Khanna D, Clements PJ, Furst DE, Tashkin DP. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. Curr Rheumatol Rep. 2009 Apr; 11(2):111-9. PMID: 19296883.
      View in: PubMed
    242. Furst DE. Certolizumab pegol--what role does this new TNF inhibitor have in the treatment of RA? Nat Clin Pract Rheumatol. 2009 Mar; 5(3):134-5. PMID: 19190623.
      View in: PubMed
    243. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum. 2010 Apr; 39(5):327-46. PMID: 19117595.
      View in: PubMed
    244. Furst DE, Keystone EC, Kirkham B, Kavanaugh A, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Burmester GR, Braun J, Emery P, Winthrop K, Bresnihan B, De Benedetti F, Dörner T, Gibofsky A, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis. 2008 Dec; 67 Suppl 3:iii2-25. PMID: 19022808.
      View in: PubMed
    245. Furst DE. Outcome measures in rheumatologic clinical trials and systemic sclerosis. Rheumatology (Oxford). 2008 Oct; 47 Suppl 5:v29-30. PMID: 18784136.
      View in: PubMed
    246. Sawitzke AD, Shi H, Finco MF, Dunlop DD, Bingham CO, Harris CL, Singer NG, Bradley JD, Silver D, Jackson CG, Lane NE, Oddis CV, Wolfe F, Lisse J, Furst DE, Reda DJ, Moskowitz RW, Williams HJ, Clegg DO. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum. 2008 Oct; 58(10):3183-91. PMID: 18821708.
      View in: PubMed
    247. Braun-Moscovici Y, Furst DE, Markovits D, Rozin A, Clements PJ, Nahir AM, Balbir-Gurman A. Vitamin D, parathyroid hormone, and acroosteolysis in systemic sclerosis. J Rheumatol. 2008 Nov; 35(11):2201-5. PMID: 18843781.
      View in: PubMed
    248. Ranganath VK, Paulus HE, Onofrei A, Khanna D, Reed G, Elashoff DA, Kremer JM, Furst DE. Functional improvement after patients with rheumatoid arthritis start a new disease modifying antirheumatic drug (DMARD) associated with frequent changes in DMARD: the CORRONA database. J Rheumatol. 2008 Oct; 35(10):1966-71. PMID: 18785317; PMCID: PMC2753191.
    249. Goldin JG, Lynch DA, Strollo DC, Suh RD, Schraufnagel DE, Clements PJ, Elashoff RM, Furst DE, Vasunilashorn S, McNitt-Gray MF, Brown MS, Roth MD, Tashkin DP. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest. 2008 Aug; 134(2):358-367. PMID: 18641099.
      View in: PubMed
    250. Furst DE. Serum immunoglobulins and risk of infection: how low can you go? Semin Arthritis Rheum. 2009 Aug; 39(1):18-29. PMID: 18620738.
      View in: PubMed
    251. Weinblatt ME, Schiff MH, Ruderman EM, Bingham CO, Li J, Louie J, Furst DE. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum. 2008 Jul; 58(7):1921-30. PMID: 18576334.
      View in: PubMed
    252. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008 Jun 15; 59(6):762-84. PMID: 18512708.
      View in: PubMed
    253. Distler O, Behrens F, Pittrow D, Huscher D, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Furst DE. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. Arthritis Rheum. 2008 Jun 15; 59(6):867-75. PMID: 18512721.
      View in: PubMed
    254. Postlethwaite AE, Wong WK, Clements P, Chatterjee S, Fessler BJ, Kang AH, Korn J, Mayes M, Merkel PA, Molitor JA, Moreland L, Rothfield N, Simms RW, Smith EA, Spiera R, Steen V, Warrington K, White B, Wigley F, Furst DE. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis Rheum. 2008 Jun; 58(6):1810-22. PMID: 18512816; PMCID: PMC4511098.
    255. Merkel PA, Silliman NP, Denton CP, Furst DE, Khanna D, Emery P, Hsu VM, Streisand JB, Polisson RP, Akesson A, Coppock J, van den Hoogen F, Herrick A, Mayes MD, Veale D, Seibold JR, Black CM, Korn JH. Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. Arthritis Rheum. 2008 May 15; 59(5):699-705. PMID: 18438905; PMCID: PMC3887555.
    256. Khanna D, Furst DE, Clements PJ, Tashkin DP, Eckman MH. Oral cyclophosphamide for active scleroderma lung disease: a decision analysis. Med Decis Making. 2008 Nov-Dec; 28(6):926-37. PMID: 18443209.
      View in: PubMed
    257. Hay MC, Cadigan RJ, Khanna D, Strathmann C, Lieber E, Altman R, McMahon M, Kokhab M, Furst DE. Prepared patients: internet information seeking by new rheumatology patients. Arthritis Rheum. 2008 Apr 15; 59(4):575-82. PMID: 18383399.
      View in: PubMed
    258. Furst DE, Khanna D. Health-related quality of life in rheumatoid arthritis. Am J Manag Care. 2008 Apr; 14(4):234. PMID: 18411491.
      View in: PubMed
    259. Antoni CE, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou B, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman DD, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen JS. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol. 2008 May; 35(5):869-76. PMID: 18381786.
      View in: PubMed
    260. Fleming JN, Nash RA, McLeod DO, Fiorentino DF, Shulman HM, Connolly MK, Molitor JA, Henstorf G, Lafyatis R, Pritchard DK, Adams LD, Furst DE, Schwartz SM. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS One. 2008 Jan 16; 3(1):e1452. PMID: 18197262; PMCID: PMC2175530.
    261. Furst DE, Halbert RJ, Bingham CO, Fukudome S, Anderson L, Bonafede P, Bray V, Cohen SB, Sherrer YR, St Clair EW, Tesser JR, Weinblatt M, Dubois RW. Evaluating the adequacy of disease control in patients with rheumatoid arthritis: a RAND appropriateness panel. Rheumatology (Oxford). 2008 Feb; 47(2):194-9. PMID: 18178593.
      View in: PubMed
    262. Khanna D, Clements PJ, Postlethwaite AE, Furst DE. Does incorporation of aids and devices make a difference in the score of the health assessment questionnaire-disability index? Analysis from a scleroderma clinical trial. J Rheumatol. 2008 Mar; 35(3):466-8. PMID: 18085737.
      View in: PubMed
    263. Furst DE, Matucci Cerinic M. Connective tissue diseases. Best Pract Res Clin Rheumatol. 2007 Dec; 21(6):969-70. PMID: 18068855.
      View in: PubMed
    264. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007 Dec; 56(12):3896-908. PMID: 18050221.
      View in: PubMed
    265. Tyndall A, Furst DE. Adult stem cell treatment of scleroderma. Curr Opin Rheumatol. 2007 Nov; 19(6):604-10. PMID: 17917542.
      View in: PubMed
    266. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Sieper J, Emery P, Keystone EC, Schiff MH, Mease P, van Riel PL, Fleischmann R, Weisman MH, Weinblatt ME. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis. 2007 Nov; 66 Suppl 3:iii2-22. PMID: 17934088; PMCID: PMC2095281.
    267. Khanna D, Hays RD, Park GS, Braun-Moscovici Y, Mayes MD, McNearney TA, Hsu V, Clements PJ, Furst DE. Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument. Arthritis Rheum. 2007 Oct 15; 57(7):1280-6. PMID: 17907224.
      View in: PubMed
    268. Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, Clements P, Chung J, Elashoff RM, Suh R, Smith EA, Furst DE, Tashkin DP. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med. 2008 Jan 01; 177(1):91-8. PMID: 17901414; PMCID: PMC2176114.
    269. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Goldin J, Arriola E, Strange C, Bolster MB, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Khanna D, Li N, Li G. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007 Nov 15; 176(10):1026-34. PMID: 17717203; PMCID: PMC2078679.
    270. Furst DE. Measuring outcomes in PAH: the gap between the measures that are used and their validity. Ann N Y Acad Sci. 2007 Jun; 1107:410-6. PMID: 17804569.
      View in: PubMed
    271. Schumacher HR, Taylor W, Joseph-Ridge N, Perez-Ruiz F, Chen LX, Schlesinger N, Khanna D, Furst DE, Becker MA, Dalbeth N, Edwards NL. Outcome evaluations in gout. J Rheumatol. 2007 Jun; 34(6):1381-5. PMID: 17552064.
      View in: PubMed
    272. Woodworth T, Furst DE, Alten R, Bingham CO, Bingham C, Yocum D, Sloan V, Tsuji W, Stevens R, Fries J, Witter J, Johnson K, Lassere M, Brooks P. Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0. J Rheumatol. 2007 Jun; 34(6):1401-14. PMID: 17552067.
      View in: PubMed
    273. Charles-Schoeman C, Khanna D, Furst DE, McMahon M, Reddy ST, Fogelman AM, Paulus HE, Park GS, Gong T, Ansell BJ. Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol. 2007 Jul; 34(7):1459-64. PMID: 17552046.
      View in: PubMed
    274. Clements PJ, Roth MD, Elashoff R, Tashkin DP, Goldin J, Silver RM, Sterz M, Seibold JR, Schraufnagel D, Simms RW, Bolster M, Wise RA, Steen V, Mayes MD, Connelly K, Metersky M, Furst DE. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis. 2007 Dec; 66(12):1641-7. PMID: 17485423; PMCID: PMC2095310.
    275. Felson DT, Furst DE, Boers M. Rationale and strategies for reevaluating the ACR20. J Rheumatol. 2007 May; 34(5):1184-7. PMID: 17477484.
      View in: PubMed
    276. Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Clements PJ. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum. 2007 May; 56(5):1676-84. PMID: 17469162.
      View in: PubMed
    277. Furst D, Khanna D, Matucci-Cerinic M, Clements P, Steen V, Pope J, Merkel P, Foeldvari I, Seibold J, Pittrow D, Polisson R, Strand V. Systemic sclerosis - continuing progress in developing clinical measures of response. J Rheumatol. 2007 May; 34(5):1194-200. PMID: 17477486.
      View in: PubMed
    278. Fathi N, Furst DE, Clements PJ. Management of interstitial lung disease in systemic sclerosis: lessons from SLS and FAST. Curr Rheumatol Rep. 2007 May; 9(2):144-50. PMID: 17502045.
      View in: PubMed
    279. Ranganath VK, Yoon J, Khanna D, Park GS, Furst DE, Elashoff DA, Jawaheer D, Sharp JT, Gold RH, Keystone EC, Paulus HE. Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort. Ann Rheum Dis. 2007 Dec; 66(12):1633-40. PMID: 17472996; PMCID: PMC2095300.
    280. Nash RA, McSweeney PA, Crofford LJ, Abidi M, Chen CS, Godwin JD, Gooley TA, Holmberg L, Henstorf G, LeMaistre CF, Mayes MD, McDonagh KT, McLaughlin B, Molitor JA, Nelson JL, Shulman H, Storb R, Viganego F, Wener MH, Seibold JR, Sullivan KM, Furst DE. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood. 2007 Aug 15; 110(4):1388-96. PMID: 17452515; PMCID: PMC1939909.
    281. Khanna D, Oh M, Furst DE, Ranganath V, Gold RH, Sharp JT, Park GS, Keystone EC, Paulus HE. Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort. Arthritis Rheum. 2007 Apr 15; 57(3):440-7. PMID: 17394230.
      View in: PubMed
    282. Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, Weisman M, Wallace DJ, Crues J, Khanna D, Eckel G, Yeilding N, Callegari P, Visvanathan S, Rojas J, Hegedus R, George L, Mamun K, Gilmer K, Troum O. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis. 2007 Jul; 66(7):893-9. PMID: 17412737; PMCID: PMC1955098.
    283. Khanna D, Furst DE, Wong WK, Tsevat J, Clements PJ, Park GS, Postlethwaite AE, Ahmed M, Ginsburg S, Hays RD. Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis. Qual Life Res. 2007 Aug; 16(6):1083-92. PMID: 17404896.
      View in: PubMed
    284. Khanna D, Ahmed M, Furst DE, Ginsburg SS, Park GS, Hornung R, Tsevat J. Health values of patients with systemic sclerosis. Arthritis Rheum. 2007 Feb 15; 57(1):86-93. PMID: 17266070.
      View in: PubMed
    285. Wong WK, Furst DE, Clements PJ, Streisand JB. Assessing disease progression using a composite endpoint. Stat Methods Med Res. 2007 Feb; 16(1):31-49. PMID: 17338293.
      View in: PubMed
    286. Ranganath VK, Furst DE. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient. Rheum Dis Clin North Am. 2007 Feb; 33(1):197-217. PMID: 17367700.
      View in: PubMed
    287. Gazi H, Pope JE, Clements P, Medsger TA, Martin RW, Merkel PA, Kahaleh B, Wollheim FA, Baron M, Csuka ME, Emery P, Belch JF, Hayat S, Lally EV, Korn JH, Czirjak L, Herrick A, Voskuyl AE, Bruehlmann P, Inanc M, Furst DE, Black C, Ellman MH, Moreland LW, Rothfield NF, Hsu V, Mayes M, McKown KM, Krieg T, Siebold JR. Outcome measurements in scleroderma: results from a delphi exercise. J Rheumatol. 2007 Mar; 34(3):501-9. PMID: 17299843.
      View in: PubMed
    288. Malcarne VL, Hansdottir I, McKinney A, Upchurch R, Greenbergs HL, Henstorf GH, Furst DE, Clements PJ, Weisman MH. Medical signs and symptoms associated with disability, pain, and psychosocial adjustment in systemic sclerosis. J Rheumatol. 2007 Feb; 34(2):359-67. PMID: 17304659.
      View in: PubMed
    289. Czirják L, Nagy Z, Aringer M, Riemekasten G, Matucci-Cerinic M, Furst DE. The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Ann Rheum Dis. 2007 Jul; 66(7):966-9. PMID: 17234649; PMCID: PMC1955103.
    290. Figueroa F, Braun-Moscovici Y, Khanna D, Voon E, Gallardo L, Luinstra D, Pina X, Henstorf G, Laurence S, Neiman R, Furst D. Patient self-administered joint tenderness counts in rheumatoid arthritis are reliable and responsive to changes in disease activity. J Rheumatol. 2007 Jan; 34(1):54-6. PMID: 17216678.
      View in: PubMed
    291. Matucci-Cerinic M, Steen VD, Furst DE, Seibold JR. Clinical trials in systemic sclerosis: lessons learned and outcomes. Arthritis Res Ther. 2007; 9 Suppl 2:S7. PMID: 17767745; PMCID: PMC2072887.
    292. Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, Streisand J, Powell J, Akesson A, Coppock J, Hoogen Fv, Herrick A, Mayes MD, Veale D, Haas J, Ledbetter S, Korn JH, Black CM, Seibold JR. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum. 2007 Jan; 56(1):323-33. PMID: 17195236.
      View in: PubMed
    293. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Emery P, Keystone EC, Schiff MH, van Riel PL, Weinblatt ME, Weisman MH. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis. 2006 Nov; 65 Suppl 3:iii2-15. PMID: 17038465; PMCID: PMC1798383.
    294. Furst DE, Khanna D, Paulus HE. Cyclooxygenase 2 controversy: thoughts on the process of discovery, development, and assessment of benefit and risk of therapies for chronic immunoinflammatory diseases of uncertain autoimmune etiology. Arthritis Rheum. 2006 Oct 15; 55(5):683-6. PMID: 17013849.
      View in: PubMed
    295. Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, Dong X, Chen W, Kim MH, Weng HH, Furst DE, Gorn A, McMahon M, Taylor M, Brahn E, Hahn BH, Tsao BP. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 2006 Sep; 54(9):2951-62. PMID: 16947629.
      View in: PubMed
    296. Chung L, Lin J, Furst DE, Fiorentino D. Systemic and localized scleroderma. Clin Dermatol. 2006 Sep-Oct; 24(5):374-92. PMID: 16966019.
      View in: PubMed
    297. Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006 Aug; 20(4):757-90. PMID: 16979537.
      View in: PubMed
    298. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006 Aug; 54(8):2688-96. PMID: 16871533.
      View in: PubMed
    299. Storek J, Nash RA, McSweeney PA, Furst DE, Sullivan KM. Normal interleukin-7 (IL7) levels and normal IL7 response to CD4 T lymphopenia in patients with multiple sclerosis and systemic sclerosis. Clin Immunol. 2006 Oct; 121(1):118-9. PMID: 16844418.
      View in: PubMed
    300. Cole JC, Khanna D, Clements PJ, Seibold JR, Tashkin DP, Paulus HE, Irwin MR, Motivala SJ, Furst DE. Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients. Qual Life Res. 2006 Oct; 15(8):1383-94. PMID: 16826439.
      View in: PubMed
    301. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum. 2006 Dec; 36(3):159-67. PMID: 16884970.
      View in: PubMed
    302. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 Jun 22; 354(25):2655-66. PMID: 16790698.
      View in: PubMed
    303. Nash RA, McSweeney PA, Nelson JL, Wener M, Georges GE, Langston AA, Shulman H, Sullivan KM, Lee J, Henstorf G, Storb R, Furst DE. Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. Arthritis Rheum. 2006 Jun; 54(6):1982-6. PMID: 16732546; PMCID: PMC2956579.
    304. Griffith LM, Pavletic SZ, Tyndall A, Gratwohl A, Furst DE, Forman SJ, Nash RA. Target populations in allogeneic hematopoietic cell transplantation for autoimmune diseases--a workshop accompanying: cellular therapy for treatment of autoimmune diseases, basic science and clinical studies, including new developments in hematopoietic and mesenchymal stem cell therapy. Biol Blood Marrow Transplant. 2006 Jun; 12(6):688-90. PMID: 16737943.
      View in: PubMed
    305. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet. 2006 May 20; 367(9523):1683-91. PMID: 16714190.
      View in: PubMed
    306. Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, Bradley JD, Bingham CO, Weisman MH, Jackson CG, Lane NE, Cush JJ, Moreland LW, Schumacher HR, Oddis CV, Wolfe F, Molitor JA, Yocum DE, Schnitzer TJ, Furst DE, Sawitzke AD, Shi H, Brandt KD, Moskowitz RW, Williams HJ. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006 Feb 23; 354(8):795-808. PMID: 16495392.
      View in: PubMed
    307. Weisman MH, Furst DE, Park GS, Kremer JM, Smith KM, Wallace DJ, Caldwell JR, Dervieux T. Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum. 2006 Feb; 54(2):607-12. PMID: 16447238.
      View in: PubMed
    308. Furst DE, Khanna D, Mattucci-Cerinic M, Silman AJ, Merkel PA, Foeldvari I. Scleroderma--developing measures of response. J Rheumatol. 2005 Dec; 32(12):2477-80. PMID: 16331791.
      View in: PubMed
    309. Wolfe F, Michaud K, Pincus T, Furst D, Keystone E. The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum. 2005 Dec; 52(12):3873-9. PMID: 16320335.
      View in: PubMed
    310. Schumacher HR, Edwards LN, Perez-Ruiz F, Becker M, Chen LX, Furst DE, Joseph-Ridge N, Schlesinger N, Horowitz Z, Saag K, Boice JA, Yamanaka H. Outcome measures for acute and chronic gout. J Rheumatol. 2005 Dec; 32(12):2452-5. PMID: 16331785.
      View in: PubMed
    311. Furst DE, Fleischmann R, Kopp E, Schiff M, Edwards C, Solinger A, Macri M. A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis. J Rheumatol. 2005 Dec; 32(12):2303-10. PMID: 16331754.
      View in: PubMed
    312. Ahmed M, Khanna D, Furst DE. Meloxicam in rheumatoid arthritis. Expert Opin Drug Metab Toxicol. 2005 Dec; 1(4):739-51. PMID: 16863437.
      View in: PubMed
    313. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, Dougados M, Emery P, Keystone EC, Klareskog L, Mease PJ. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis. 2005 Nov; 64 Suppl 4:iv2-14. PMID: 16239380; PMCID: PMC1766920.
    314. Khanna D, Park GS, Paulus HE, Simpson KM, Elashoff D, Cohen SB, Emery P, Dorrier C, Furst DE. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies. Arthritis Rheum. 2005 Oct; 52(10):3030-8. PMID: 16200612.
      View in: PubMed
    315. Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, Aletaha D, Anderson JJ, Bombardier C, Dougados M, Emery P, Felson DT, Fransen J, Furst DE, Hazes JM, Johnson KR, Kirwan JR, Landewé RB, Lassere MN, Michaud K, Suarez-Almazor M, Silman AJ, Smolen JS, Van der Heijde DM, van Riel PL, Wolfe F, Tugwell PS. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol. 2005 Oct; 32(10):2016-24. PMID: 16206362.
      View in: PubMed
    316. Lassere MN, Johnson KR, Woodworth TG, Furst DE, Fries JF, Kirwan JR, Tugwell PS, Day RO, Brooks PM. Challenges and progress in adverse event ascertainment and reporting in clinical trials. J Rheumatol. 2005 Oct; 32(10):2030-2. PMID: 16206364.
      View in: PubMed
    317. Lassere MN, Johnson KR, Boers M, Carlton K, Day RO, de Wit M, Edwards IR, Fries JF, Furst DE, Kirwan JR, Tugwell PS, Woodworth TG, Brooks PM. Standardized assessment of adverse events in rheumatology clinical trials: summary of the OMERACT 7 drug safety module update. J Rheumatol. 2005 Oct; 32(10):2037-41. PMID: 16206366.
      View in: PubMed
    318. Khanna D, Ranganath VK, Fitzgerald J, Park GS, Altman RD, Elashoff D, Gold RH, Sharp JT, Furst DE, Paulus HE. Increased radiographic damage scores at the onset of seropositive rheumatoid arthritis in older patients are associated with osteoarthritis of the hands, but not with more rapid progression of damage. Arthritis Rheum. 2005 Aug; 52(8):2284-92. PMID: 16052588.
      View in: PubMed
    319. Ranganath VK, Furst DE. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient. Clin Geriatr Med. 2005 Aug; 21(3):649-69, viii. PMID: 15911212.
      View in: PubMed
    320. Furst DE. Measuring the impact of managed care plans on the use of biologics. Arthritis Rheum. 2005 Jun 15; 53(3):318-9. PMID: 15934125.
      View in: PubMed
    321. Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, Korn JH, Merkel PA, Rothfield N, Wigley FM, Moreland LW, Silver R, Steen VD, Weisman M, Mayes MD, Collier DH, Medsger TA, Seibold JR. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol. 2005 May; 32(5):832-40. PMID: 15868618.
      View in: PubMed
    322. de Buys P, Khanna D, Furst DE. Hemopoietic stem cell transplantation in rheumatic diseases--an update. Autoimmun Rev. 2005 Sep; 4(7):442-9. PMID: 16137610.
      View in: PubMed
    323. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005 Apr; 52(4):1227-36. PMID: 15818699.
      View in: PubMed
    324. Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, Sterz MG, Chung J, FitzGerald JD, Seibold JR, Varga J, Theodore A, Wigley FM, Silver RM, Steen VD, Mayes MD, Connolly MK, Fessler BJ, Rothfield NF, Mubarak K, Molitor J, Tashkin DP. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum. 2005 Feb; 52(2):592-600. PMID: 15692967.
      View in: PubMed
    325. Burt RK, Furst DE, Weisman MH, Sullivan KE. Ruminating on rheumatoid arthritis and transplantation. Clin Immunol. 2005 May; 115(2):129-30. PMID: 15885633.
      View in: PubMed
    326. Khanna D, Khanna PP, Furst DE. COX-2 controversy: where are we and where do we go from here? Inflammopharmacology. 2005; 13(4):395-402. PMID: 16354392.
      View in: PubMed
    327. Krishnan E, Furst DE. Systemic sclerosis mortality in the United States: 1979-1998. Eur J Epidemiol. 2005; 20(10):855-61. PMID: 16283476.
      View in: PubMed
    328. Furst DE. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. Clin Ther. 2004 Dec; 26(12):1960-75. PMID: 15823761.
      View in: PubMed
    329. Furst DE, Nash R, Sullivan KM, Saccardi R, McSweeney P. High dose immunotherapy with stem cell rescue in severe systemic sclerosis: an idea that is moving forward. J Rheumatol. 2004 Dec; 31(12):2331-5. PMID: 15570631.
      View in: PubMed
    330. Storek J, Zhao Z, Lin E, Berger T, McSweeney PA, Nash RA, Akatsuka Y, Metcalf MD, Lu H, Kalina T, Reindl M, Storb R, Hansen JA, Sullivan KM, Kraft GH, Furst DE, Maloney DG. Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases). Clin Immunol. 2004 Dec; 113(3):285-98. PMID: 15507394; PMCID: PMC2956741.
    331. Dervieux T, Kremer J, Lein DO, Capps R, Barham R, Meyer G, Smith K, Caldwell J, Furst DE. Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics. 2004 Nov; 14(11):733-9. PMID: 15564880.
      View in: PubMed
    332. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, Dougados M, Emery P, Keystone EC, Klareskog L, Mease PJ. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis. 2004 Nov; 63 Suppl 2:ii2-ii12. PMID: 15479866; PMCID: PMC1766772.
    333. Beenhouwer D, Wallis R, Broder M, Furst DE. Mechanisms of action of tumor necrosis factor antagonist and granulomatous infections. J Rheumatol. 2004 Oct; 31(10):1888-92. PMID: 15487038.
      View in: PubMed
    334. Furst DE. Window of opportunity. J Rheumatol. 2004 Sep; 31(9):1677-9. PMID: 15338482.
      View in: PubMed
    335. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, Kremer J. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 2004 Sep; 50(9):2766-74. PMID: 15457444.
      View in: PubMed
    336. Furst DE. Observational cohort studies and well controlled clinical trials--we need them both! J Rheumatol. 2004 Aug; 31(8):1476-7. PMID: 15290723.
      View in: PubMed
    337. Kremer J, Genovese M, Cannon GW, Caldwell J, Cush J, Furst DE, Luggen M, Keystone E, Bathon J, Kavanaugh A, Ruderman E, Coleman P, Curtis D, Kopp E, Kantor S, Weisman M, Waltuck J, Lindsley HB, Markenson J, Crawford B, Fernando I, Simpson K, Strand V. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. J Rheumatol. 2004 Aug; 31(8):1521-31. PMID: 15290730.
      View in: PubMed
    338. Clements PJ, Goldin JG, Kleerup EC, Furst DE, Elashoff RM, Tashkin DP, Roth MD. Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis Rheum. 2004 Jun; 50(6):1909-17. PMID: 15188367.
      View in: PubMed
    339. Khanna D, McMahon M, Furst DE. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheum. 2004 Apr; 50(4):1040-50. PMID: 15077286.
      View in: PubMed
    340. Lambert NC, Erickson TD, Yan Z, Pang JM, Guthrie KA, Furst DE, Nelson JL. Quantification of maternal microchimerism by HLA-specific real-time polymerase chain reaction: studies of healthy women and women with scleroderma. Arthritis Rheum. 2004 Mar; 50(3):906-14. PMID: 15022334.
      View in: PubMed
    341. Clements PJ, Seibold JR, Furst DE, Mayes M, White B, Wigley F, Weisman MD, Barr W, Moreland L, Medsger TA, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Wong WK. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. Semin Arthritis Rheum. 2004 Feb; 33(4):249-63. PMID: 14978663.
      View in: PubMed
    342. Furst DE. Acquired resistance of human T cells to sulfasalazine. Ann Rheum Dis. 2004 Feb; 63(2):115-6. PMID: 14722196; PMCID: PMC1754893.
    343. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf. 2004; 27(5):307-24. PMID: 15061685.
      View in: PubMed
    344. Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003 Dec; 30(12):2563-71. PMID: 14719195.
      View in: PubMed
    345. Yocum DE, Furst DE, Kaine JL, Baldassare AR, Stevenson JT, Borton MA, Mengle-Gaw LJ, Schwartz BD, Wisemandle W, Mekki QA. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. Arthritis Rheum. 2003 Dec; 48(12):3328-37. PMID: 14673984.
      View in: PubMed
    346. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Dougados M, Emery P, Gibofsky A, Kavanaugh AF, Keystone EC, Klareskog L, Russell AS, van de Putte LB, Weisman MH, Kavenaugh AF. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Ann Rheum Dis. 2003 Nov; 62 Suppl 2:ii2-9. PMID: 14532138; PMCID: PMC1766759.
    347. Furst DE, Weisman M, Paulus HE, Bulpitt K, Weinblatt M, Polisson R, Zaug M, Kneer J, Van der Auwera P, Stevens RM. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritis. J Rheumatol. 2003 Oct; 30(10):2123-6. PMID: 14528504.
      View in: PubMed
    348. Nash RA, Dansey R, Storek J, Georges GE, Bowen JD, Holmberg LA, Kraft GH, Mayes MD, McDonagh KT, Chen CS, Dipersio J, Lemaistre CF, Pavletic S, Sullivan KM, Sunderhaus J, Furst DE, McSweeney PA. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant. 2003 Sep; 9(9):583-91. PMID: 14506660; PMCID: PMC2956744.
    349. Russak SM, Croft JD, Furst DE, Hohlbauch A, Liang MH, Moreland L, Ofman JJ, Paulus H, Simon LS, Weisman M, Tugwell P. The use of rheumatoid arthritis health-related quality of life patient questionnaires in clinical practice: lessons learned. Arthritis Rheum. 2003 Aug 15; 49(4):574-84. PMID: 12910566.
      View in: PubMed
    350. Furst DE. Comment on Furst's Editorial: Postmarketing Surveys: Up Sides and Down Sides: In Reply to "Comment on Furst Editorial: Postmarketing Surveys, Upsides and Downsides". J Clin Rheumatol. 2003 Aug; 9(4):280-1. PMID: 19078532.
      View in: PubMed
    351. Merkel PA, Clements PJ, Reveille JD, Suarez-Almazor ME, Valentini G, Furst DE. Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol. 2003 Jul; 30(7):1630-47. PMID: 12858472.
      View in: PubMed
    352. Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003 Jun; 25(6):1700-21. PMID: 12860493.
      View in: PubMed
    353. Lin AT, Clements PJ, Furst DE. Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosis. Rheum Dis Clin North Am. 2003 May; 29(2):409-26. PMID: 12841302.
      View in: PubMed
    354. Braun-Moscovici Y, Furst DE. Immunoglobulin for rheumatic diseases in the twenty-first century: take it or leave it? Curr Opin Rheumatol. 2003 May; 15(3):237-45. PMID: 12707576.
      View in: PubMed
    355. Braun-Moscovici Y, Furst DE. Plasmapheresis for rheumatic diseases in the twenty-first century: take it or leave it? Curr Opin Rheumatol. 2003 May; 15(3):197-204. PMID: 12707571.
      View in: PubMed
    356. Kavanaugh A, Genovese M, Baughman J, Kivitz A, Bulpitt K, Olsen N, Weisman M, Matteson E, Furst D, van Vollenhoven R, Anderson J, Cohen S, Wei N, Meijerink J, Jacobs C, Mocci S. Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trial. J Rheumatol. 2003 Mar; 30(3):449-54. PMID: 12610799.
      View in: PubMed
    357. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003 Jan; 48(1):35-45. PMID: 12528101.
      View in: PubMed
    358. Seidman EG, Furst DE. Pharmacogenetics for the individualization of treatment of rheumatic disorders using azathioprine. J Rheumatol. 2002 Dec; 29(12):2484-7. PMID: 12465139.
      View in: PubMed
    359. Furst DE. Postmarketing surveys: up sides and down sides. J Clin Rheumatol. 2002 Dec; 8(6):295-6. PMID: 17041396.
      View in: PubMed
    360. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, Luggen ME, Keystone E, Weisman MH, Bensen WM, Kaine JL, Ruderman EM, Coleman P, Curtis DL, Kopp EJ, Kantor SM, Waltuck J, Lindsley HB, Markenson JA, Strand V, Crawford B, Fernando I, Simpson K, Bathon JM. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002 Nov 05; 137(9):726-33. PMID: 12416946.
      View in: PubMed
    361. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Antoni CE, Bijlsma JW, Burmester GR, Cronstein B, Keystone EC, Kavanaugh A, Klareskog L. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis. 2002 Nov; 61 Suppl 2:ii2-7. PMID: 12379612; PMCID: PMC1766714.
    362. Braun-Moscovici Y, Furst DE. Stem cell therapy in scleroderma. Curr Opin Rheumatol. 2002 Nov; 14(6):711-6. PMID: 12410096.
      View in: PubMed
    363. DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, Mayes M, White B, Wigley F, Barr W, Moreland L, Medsger TA, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Clements PJ. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum. 2002 Nov; 46(11):2983-9. PMID: 12428241.
      View in: PubMed
    364. Lambert NC, Lo YM, Erickson TD, Tylee TS, Guthrie KA, Furst DE, Nelson JL. Male microchimerism in healthy women and women with scleroderma: cells or circulating DNA? A quantitative answer. Blood. 2002 Oct 15; 100(8):2845-51. PMID: 12351394.
      View in: PubMed
    365. Fathi NH, Mitros F, Hoffman J, Straniero N, Labreque D, Koehnke R, Furst DE. Longitudinal measurement of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3.5 year double blind study in rheumatoid arthritis. J Rheumatol. 2002 Oct; 29(10):2092-8. PMID: 12375317.
      View in: PubMed
    366. Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, Korn JH, Simms RW, Csuka ME, Medsger TA, Rothfield NF, Ellman MH, Collier DH, Weinstein A, Furst DE, Jiménez SA, White B, Seibold JR, Wigley FM. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum. 2002 Sep; 46(9):2410-20. PMID: 12355489.
      View in: PubMed
    367. McSweeney PA, Nash RA, Sullivan KM, Storek J, Crofford LJ, Dansey R, Mayes MD, McDonagh KT, Nelson JL, Gooley TA, Holmberg LA, Chen CS, Wener MH, Ryan K, Sunderhaus J, Russell K, Rambharose J, Storb R, Furst DE. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood. 2002 Sep 01; 100(5):1602-10. PMID: 12176878; PMCID: PMC2956742.
    368. Furst DE, Saag K, Fleischmann MR, Sherrer Y, Block JA, Schnitzer T, Rutstein J, Baldassare A, Kaine J, Calabrese L, Dietz F, Sack M, Senter RG, Wiesenhutter C, Schiff M, Stein CM, Satoi Y, Matsumoto A, Caldwell J, Harris RE, Moreland LW, Hurd E, Yocum D, Stamler DA. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum. 2002 Aug; 46(8):2020-8. PMID: 12209503.
      View in: PubMed
    369. Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J, Dietz F, Ettlinger R, Golden HE, Lindsley H, McLaughlin GE, Moreland LW, Roberts WN, Rooney TW, Rothschild B, Sack M, Sebba AI, Weisman M, Welch KE, Yocum D, Furst DE. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002 Jun; 46(6):1460-9. PMID: 12115175.
      View in: PubMed
    370. Furst DE. Stem cell transplantation for autoimmune disease: progress and problems. Curr Opin Rheumatol. 2002 May; 14(3):220-4. PMID: 11981316.
      View in: PubMed
    371. Furst DE, Kolba KS, Fleischmann R, Silverfield J, Greenwald M, Roth S, Hall DB, Roszko PJ. Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac. J Rheumatol. 2002 Mar; 29(3):436-46. PMID: 11908554.
      View in: PubMed